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ABSTRACT
Morphine has been and continues to be one of the most potent and widely used
drugs for the treatment of pain. Clinical and animal models investigating sex differences
in pain and analgesia demonstrate that morphine is a more potent analgesic in males
than in females; indeed, we report the effective dose of morphine for female rats is twice
that of male rats. In addition to binding to the neuronal mu opioid receptor, morphine
binds to the innate immune receptor toll-like receptor 4 (TLR4) on microglia. Morphine
action at TLR4 initiates a neuroinflammatory response and directly opposes morphine
analgesia. Our recent studies demonstrate that administration of chronic morphine
activates microglia within the ventrolateral periaqueductal gray (vlPAG), a critical brain

region for the antinociceptive effects of morphine, while blockade of vlPAG microglia
increases morphine analgesia and suppresses the development of tolerance in male
rats. Despite increasing evidence of the involvement of microglia in altering morphine
efficacy, no studies have examined sex differences in microglia within the PAG. The
present experiments seek to characterize the distribution and activity of vlPAG microglia
in males and females using behavioral, immunohistochemical and molecular
techniques, while demonstrating the sufficiency and necessity of vlPAG microglia to
produce sex differences in morphine analgesia using site-specific pharmacological
manipulation of TLR4. We also investigate a novel pharmacokinetic mechanism
underlying the sexually dimorphic effects of morphine administration on microglial
activity. Here, we address a fundamental gap in our current understanding of sex
differences in morphine analgesia and establish a mechanistic understanding of how
the activation of vlPAG microglia sex-specifically influences morphine analgesia.
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1 INTRODUCTION
Sex differences in pain and treatment
Pain is a highly subjective and unpleasant experience arising from the central
nervous system. The perception of pain evolved as a protective mechanism to avoid
potentially fatal encounters, and to discourage or change harmful behavior. However,
pain does not always occur as a result of an overt injury; in some cases, the cause of
pain cannot be identified. In these instances, long-lasting pain may become a frustrating
and debilitating disease in and of itself--and can be extremely difficult to manage, let
alone treat.
Chronic pain--generally defined as pain lasting longer than three to six months--is
one of the most commonly reported health problems in the US (Elzahaf et al., 2012;
Kennedy et al., 2014). The National Health Interview Survey, conducted by the National
Institutes of Health, reports that 55.7% of American adults had some level of pain within
the previous three months, while 11.2 % had experienced chronic pain, that is, pain
every day for the three months prior to the survey (Nahin, 2015). With so many
individuals suffering from pain, it is no surprise that the economic burden of pain is
massive. The National Academy of Sciences estimates the total annual cost of pain
treatment to ranges from $560 to $635 billion annually in direct and indirect costs
(Medicine, 2011).
Chronic pain is a social and economic burden that impacts a large number of
Americans, however, women appear to be disproportionately affected. Indeed, women
have a much higher incidence rate of chronic pain conditions such as fibromyalgia,
migraine, temporomandibular disorder, and osteoarthritis (Unruh, 1996; Fillingim et al.,
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2009; Mogil, 2012; Ruau et al., 2012; Buse et al., 2013; Kennedy et al., 2014). It is
unclear if the female predominance of chronic pain conditions is due to higher
susceptibility, or a greater likelihood for women to report pain, though many studies
have attempted to tease apart these factors. Although women do use health care
services more often than men for both painful and non-painful conditions (Bertakis et al.,
2000; Prevention, 2014), a recent report demonstrates that among men and women
with the same diagnosis, reported pain levels were significantly higher in women (Ruau
et al., 2012).
Despite many years of study, it remains unclear if sex differences truly exist in pain
perception. Human subjects show variable responses to experimentally induced pain,
and sex differences in pain sensitivity are not always observed (Fillingim et al., 2009).
This may be attributed to variability in testing conditions (i.e. the modality of pain being
tested, reporting methods [self-report vs. threshold latency], or stage of menstrual
cycle). However, when sex differences are observed, these studies overwhelmingly
demonstrate that women are more sensitive to pain, and are more negatively affected
by pain, than men [see (Fillingim et al., 2009; Mogil, 2012) for review].

Opioids for the management of pain
Opium derived from poppy plants has been used for thousands of years to
alleviate pain and a variety of other ailments. Beginning in the early 1800’s, with the
extraction of morphine from opium, opioids have been—and continue to be—the most
effective and widely used pain treatment in the world (Rosenblum et al., 2008; Trescot
et al., 2008). Approximately 3-5% of the adult US population is currently prescribed long
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term opioid therapy (Boudreau et al., 2009); however, opioids induce many negative
peripheral effects that prevent them from being efficacious when used long term. For
example, opioids can induce respiratory depression and gastric immotility (Pasternak
and Pan, 2013). In addition, prolonged use of opioids reduces their analgesic efficacy
over time, thus requiring steadily larger doses to maintain analgesia—a phenomenon
known as tolerance (Trescot et al., 2006; Trescot et al., 2008). Analgesic tolerance is
reported to significantly impair pain relief (Gulur et al., 2014), and subsequent dose
escalation increases the risk of developing addiction (Trescot et al., 2006). Finally, both
chronic and acute opioid administration may result in opioid induced hyperalgesia, a
paradoxical effect of opioids resulting in enhanced sensitivity to pain (see (Angst and
Clark, 2006) for review).
Of pain sufferers, women are more likely to be prescribed opioids—at higher
doses and for longer periods of time—than men (Campbell et al., 2010; Frenk et al.,
2015; Manubay et al., 2015). This may have potentially important implications for the
development of tolerance and addiction to opioids. From 1999 to 2015, more than
183,000 people in the U.S. died from overdoses related to prescription opioids (Rudd et
al., 2016), and in 2014, nearly two million Americans abused, or were dependent on,
prescription opioids (2015). Although men are more likely to die from drug overdose
than women, between 1999 and 2010, overdose deaths due to opioid pain relievers
increased by 265% in men but increased by 415% in women ((CDC), 2013).
There is increasing evidence suggesting that neither chronic nor acute treatment
with opioids is an effective strategy for pain relief in women. Women consistently
experience a greater preponderance of the negative side effects associated with acute
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opioid consumption, including nausea, dysphoria, headache, and vomiting than men
(Myles et al., 1997; Cepeda et al., 2003; Fillingim et al., 2005; Comer et al., 2010). In
addition, opioids may not offer the same degree of pain relief in women. Similar to sex
differences in pain sensitivity, sex differences in clinical pain management are also
varied and misunderstood [see (Fillingim et al., 2009) for review]. Although several
studies report that there is no sex difference in the analgesic efficacy of opioids in
humans (Sarton et al., 2000; Glasson et al., 2002; Fillingim et al., 2005; Bijur et al.,
2008), when sex differences in opioid pain relief are detected, they demonstrate
decreased analgesic efficacy in women (Cepeda and Carr, 2003; Miller and Ernst,
2004; Aubrun et al., 2005).
In contrast to clinical studies, preclinical research on pain relief using a variety of
acute and persistent pain assays in rodents have repeatedly and consistently
demonstrated that morphine is more effective in males than in females, with females
requiring approximately twice as much morphine to achieve comparable pain-relief
(Kepler et al., 1989; Boyer et al., 1998; Craft et al., 1999; Cicero et al., 2002;
Krzanowska et al., 2002; Holtman et al., 2003; Ji et al., 2006; Loyd and Murphy, 2006;
Wang et al., 2006; Loyd et al., 2008a; Posillico et al., 2015). Furthermore, several
studies indicate that females also have greater morphine-induced hyperalgesia than
their male counterparts (Holtman and Wala, 2005; Juni et al., 2008). Sex differences in
opioid analgesia are not limited to morphine, indeed, greater pain relief is observed in
male rats for almost every opioid tested (Barrett et al., 2002; Terner et al., 2003; Stoffel
et al., 2005; Peckham and Traynor, 2006; Bai et al., 2015).
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Figure 1.1.1 Inclusion of Sex in Preclinical Studies of Pain. (Mogil, 2012)

Together, these studies clearly illustrate the necessity of sex-specific research on
pain and pain management; however, the overwhelming majority of preclinical studies
of pain (approximately 79%; Figure 1.1.1) are conducted exclusively in males (Mogil,
2012). The study of pain and effective pain management in both sexes is not only
important to ease the economic burden caused by chronic pain, but it is paramount to
improve the lives of the immense number of men and women that suffer from chronic
pain daily.

Mechanisms of pain and analgesia in the central nervous system
Painful stimuli originating from the periphery are transduced by nociceptive fibers of
the spinothalamic tract that are able to detect thermal or mechanical pain. Activation of
pain-sensing channels results in excitation of two main classes of nociceptive fibers:
myelinated A-delta fibers and unmyelinated C-fibers; contributing to sharp momentary
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pain and slow diffuse pain, respectively. The signal of pain is transmitted via nociceptive
afferents from the periphery to lamina I and II of the dorsal horn of the spinal cord, then
to laminae IV-VI. Here, the signal crosses the midline and ascends to the brainstem,
thalamus, rostral ventral medulla (RVM), periaqueductal gray (PAG), and ultimately to
the cortex where pain is perceived (Millan, 1999).
While ascending pathways alert the brain to painful stimuli (nociception), descending
pathways carefully control and reduce pain (antinociception). The ventrolateral midbrain
periaqueductal gray (vlPAG), and its descending projections to the rostral ventral
medulla (RVM), are essential to exert control over antinociception (Basbaum et al.,
1978; Behbehani and Fields, 1979; Fields and Heinricher, 1985). For example, electrical
stimulation of the PAG is sufficient to induce robust analgesia, such that invasive
surgery can be performed in the absence of anesthesia (Reynolds, 1969). This effect
appears to be opioid-dependent, as intra-PAG injection of the mu opioid receptor (MOR)
antagonist (-)-naloxone attenuates stimulation-induced analgesia (Akil et al., 1976).
Morphine and other opioids bind to neuronal MORs to modulate pain. (Jensen and
Yaksh, 1986; Bernal et al., 2007; Loyd et al., 2008a). Activation of neuronal G-protein
coupled MOR decreases the conductance of voltage-gated calcium channels and opens
potassium channels, reducing the membrane potential to ultimately inhibit cell firing and
decrease the probability of presynaptic neurotransmitter release (Millan, 2002). This
effect occurs at several key sites (Figure 1.2.1):
1) In the spinal cord, MOR-induced inhibition of neurons reduces the release of pronociceptive transmitters (e.g. Substance P) from peripheral sensory neurons to
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secondary ascending spinal neurons to decrease pain transmission, ultimately
producing antinociception, or analgesia (Millan, 2002).
2) The PAG contains a high density of MOR-containing neurons (Gutstein et al.,
1998; Commons et al., 1999; Wang and Wessendorf, 2002), and MOR binding at
inhibitory GABAergic interneurons within the PAG decreases firing to descending paininhibiting neurons. This is thought to disinhibit the PAG-RVM circuit, producing a net
activation of the PAG-RVM, and inhibition of pain transmission at the spinal cord (AlHasani and Bruchas, 2011; Stein, 2013; Lau and Vaughan, 2014). The importance of
the PAG to opioid action and descending antinociception is further demonstrated as
microinjection of opiate agonists directly into the PAG induces robust analgesia in male
rats (Sohn et al., 2000; Loyd et al., 2008a). In addition, site-specific lesions of MORpositive neurons within the PAG significantly reduce the analgesic action of systemic
morphine in male rats (Loyd et al., 2008a).

Figure 1.2.1 A Model of Descending Analgesia.
This figure demonstrates two key sites of opioid action in the CNS. Adapted from (Al-Hasani and
Bruchas, 2011).
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The PAG and its projections to the RVM and spinal cord possess innate sex
differences in their anatomy and physiology that influence pain management and the
effectiveness of opioid drugs. Specifically, our previous studies have found that females
have approximately twice as many output neurons in the PAG-RVM pathway as their
male counterparts; however, PAG-RVM output neurons are preferentially activated in
males during persistent pain or following morphine injection (Loyd and Murphy, 2006;
Loyd et al., 2007). In addition, males appear to have greater levels of MOR expression
and binding within the PAG, likely contributing to the increased analgesic efficacy of
morphine in males (Loyd et al., 2008a). However, selective ablation of vlPAG MORexpressing neurons significantly attenuates the response to morphine exclusively in
males, indicating that the density of PAG MOR expression is significantly correlated with
the degree of opioid analgesia in male, but not female, rats (Loyd et al., 2008a). These
studies indicate that although MOR tone in the PAG is sexually dimorphic, density of
MOR alone cannot solely account for the decreased efficacy of morphine observed in
females.

Morphine action: pharmacokinetics, pharmacodynamics, and sex
differences
Following administration ~10% of morphine is directly absorbed or excreted
unchanged (Christrup, 1997). The remaining ~90% of morphine is metabolized to form
two active metabolites: morphine-3-glucuronide (M3G) and morphine-6-glucuronide
(M6G). Metabolism occurs primarily in the liver (Coffman et al., 1997), but also by
peripheral macrophages (Tochigi et al., 2005) and brain microglia (Togna et al., 2013),

9

indicating both peripheral and central metabolism of morphine. Isozymes in the uridine
5'-diphospho-glucuronosyltransferase (UGT) 1 and 2 subfamilies metabolize morphine
by addition of a glucuronic acid to the morphine substrate via Phase II metabolism
(Coughtrie et al., 1989; Christrup, 1997). Peripheral enzymes UGT 1A1, 1A3, 1A6, 1A8,
1A9, 1A10, and 2B7 are all capable of M3G glucuronidation, but M6G can only be
formed by UGT2B7 in humans (Stone et al., 2003). In rats, the UGT 1A1, 1A6, 1A7, and
2B1 enzymes synthesize both M3G and M6G (Togna et al., 2013). Almost all UGT
enzymes preferentially synthesize M3G over M6G (~45-55% and 15% of metabolized
product, respectively; (De Gregori et al., 2012)).
Primary morphine metabolites have unique—and opposing—pharmacodynamic
properties. M6G binds to MOR with high affinity and is a potent analgesic (Abbott and
Palmour, 1988; Wittwer and Kern, 2006). Indeed, a recent meta-analysis suggests a
substantial contribution of M6G to total analgesia following morphine administration
(approx. 85-96%; (Klimas and Mikus, 2014)). On the other hand, M3G does not bind to
MOR or produce analgesia (Loser et al., 1996). Rather, M3G produces allodynia (pain
in response to a normally non-noxious stimuli) and hyperalgesia (exaggerated pain in
response to a normally mild painful stimulus) (Lewis et al., 2010; Due et al., 2012).
Further, administration of M3G is correlated with nociception (Smith and Smith, 1995)
and behavioral excitation (e.g. “wet dog shakes”, excessive grooming) (Yaksh et al.,
1986; Bartlett et al., 1994), and actively opposes the analgesic effects of morphine and
M6G (Smith et al., 1990; Ekblom et al., 1993).
There is evidence to suggest sex differences are also present in morphine
pharmacokinetics. For example, sexual dimorphism of UGT1 and 2 enzymes has been
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observed in humans (Gallagher et al., 2010) and rats (Iwano et al., 2012); however, this
is not surprising, given that these enzymes metabolize—and are directly influenced
by—steroid hormones (Strasser et al., 1997). Although clinical studies show both the
presence (Murthy et al., 2002) and absence (Sarton et al., 2000) of sex differences in
glucuronide concentrations in humans, animal studies of morphine metabolites
consistently show that M3G serum concentrations are ~2 times higher and the plasma
ratio of M3G to morphine is ~5.5 times higher in female than in male rats (South et al.,
2001; Baker and Ratka, 2002; South et al., 2009).

Immune modulation of pain
Pain transmission is dynamic and variable, and carefully modulated at every step
from the periphery to the CNS. Pain can be “turned down” by descending
antinociceptive processes such as endogenous opioid release and MOR binding, but it
can also be “turned up” by pro-nociceptive processes stemming from the immune
system. Although neurons have been the primary focus of pain transmission, nonneuronal glial cells of the CNS, primarily microglia and astrocytes, are in key positions
to modulate neuronal signaling and influence nociception.
Astrocytes surround neurons at the synapse, and actively participate in neuronal
signaling (Haydon et al., 2009). Microglia layer themselves across the brain and survey
the neuronal space for pathogens or chemicals associated with cellular distress, known
as “alarmins” (Davalos et al., 2005; Bianchi, 2007). In the event of cellular distress (e.g.
tissue injury or the presence of pathogens/bacteria), neurons release “alarmins” such as
fractalkine (CX3CL1), nitric oxide, substance P, calcitonin gene related peptide, ATP,
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glutamate and prostaglandins (Watkins et al., 2007; Watkins et al., 2009). These
“alarmins” bind to pattern recognition receptors, known as “toll-like” receptors (TLRs),
located primarily on microglia, and to a lesser extent, on astrocytes (Hutchinson et al.,
2008a; Watkins et al., 2009). Binding of pathogenic or damage-associated molecules to
microglial toll-like receptor 4 (TLR4) results in the transition of microglia from a ‘resting’
to a ‘reactive’ (or ‘activated’) state (Watkins and Maier, 2003; Bianchi, 2007; Watkins et
al., 2009; Buchanan et al., 2010).
‘Activated’ microglia are primary contributors to pain modulation. Microglia release
pro-nociceptive molecules such as cytokines (interleukins [IL]-1, -6, and -10; tumor
necrosis factor [TNF]), chemokines, cyclooxygenase-2 (COX-2), prostaglandin E2
(PGE2), and reactive oxygen species (Bonizzi and Karin, 2004; Doyle and O'Neill,
2006). These glial products cause down-regulation of inhibitory GABAA receptors and
up-regulation of excitatory AMPA and NMDA receptors on neurons, and decrease
glutamate transporters to increase extracellular concentrations of glutamate, together
producing a net increase in neural excitability (Ogoshi et al., 2005; Stellwagen et al.,
2005; Watkins et al., 2005; Yan et al., 2014; Eidson et al., 2016); also see (Tilleux and
Hermans, 2007) for review. Glial release of pro-inflammatory molecules and subsequent
neuronal excitability results in the sensitization of nociceptive neurons and enhanced
pain (Watkins and Maier, 2003).
Activation of CNS microglia, and subsequent release of pro-inflammatory mediators,
is now well-established to play a role in pain. For example, ‘activated’ microglia are
observed in essentially every known animal model of clinical pain, including nerve
damage, bone cancer, migraine, and many others [see (Watkins et al., 2007) for
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review]. Furthermore, activation of glial cells with inflammatory CFA (complete Freund’s
adjuvant) or the TLR4 agonist lipopolysaccharide (LPS; a component of gram-negative
bacteria), induces robust allodynia and hyperalgesia (Watkins et al., 1994;
Raghavendra et al., 2004a; Sorge et al., 2011). On the other hand, blocking glial cell
function or glial release of pro-inflammatory molecules prevents or reverses allodynia
and hyperalgesia (Maier and Watkins, 1998; Plunkett et al., 2001; Raghavendra et al.,
2003; Ledeboer et al., 2005; Hutchinson et al., 2008a). These data demonstrate that
glial cells, via TLR4, communicate bidirectionally with neurons, and their activation is
associated with increased nociception.

Opioids bind to immune receptors on glia
Microglia and astrocytes are relatively new targets in the search for improved
pain therapeutics (Tanga et al., 2005; Milligan and Watkins, 2009; Nicotra et al., 2012).
Morphine binds to the myeloid differentiation factor 2 (MD2) co-receptor of TLR4
(Hutchinson et al., 2010). Thus, similar to pathogenic molecules, morphine can initiate a
pro-inflammatory cascade, ultimately leading to cytokine release and neuronal
excitation that paradoxically reduces its own analgesic efficacy (Stellwagen et al., 2005;
Hutchinson et al., 2007; Hutchinson et al., 2010; Franchi et al., 2012; Li, 2012; Eidson
and Murphy, 2013a; Thomas et al., 2015). Unlike the MOR which can only bind the
negative isomer of opioids, TLR4 binds opioids in a non-stereoselective fashion, such
that both negative (-) and positive (+) isomers bind to TLR4 to affect glial signaling
(Hutchinson et al., 2010) (Figure 1.3.1). It is important to note that although MORs have
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been localized on microglia (Chao et al., 1997), acute morphine does not activate
microglia via MOR (Gessi et al., 2016).

Figure 1.3.1. TLR4 Binds (-) and (+) Isomers of Opioid Ligands.
TLR4 binds opioids in a nonstereoselective fashion. Adapted from (Hutchinson et al., 2010) and (Eidson
et al., 2016).

To date, many studies have shown a link between glial activation and decreased
morphine efficacy. Activation of TLR4 by morphine has also been linked with many of
the negative side effects associated with morphine use, such as morphine-induced
hyperalgesia (Raghavendra et al., 2004b), withdrawal (Ledeboer et al., 2007), and
tolerance (Song and Zhao, 2001; Raghavendra et al., 2002; Raghavendra et al., 2004b;
Mika et al., 2009; Bai et al., 2014). Inhibition of microglia or TLR4 signaling, or blockade
of proinflammatory cytokine production, result in a potentiation of morphine-induced
analgesia (Raghavendra et al., 2004b; Watkins et al., 2005; Hutchinson et al., 2008b;
Hutchinson et al., 2008a; Hutchinson et al., 2010; Li, 2012; Eidson and Murphy, 2013a;
Bai et al., 2014).
We have recently reported that the PAG is a critical neural target for morphineinduced glial activation and pain modulation in male rats. Chronic systemic
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administration of morphine activates TLR4 within the PAG to induce local cytokine
release and oppose analgesia (Eidson and Murphy, 2013b; Eidson et al., 2016).
Further, specific inhibition of TLR4 with (+)-naloxone directly into the PAG increases
analgesia and blocks the development of tolerance to chronic morphine (Eidson and
Murphy, 2013a; Eidson et al., 2016).
Morphine binding at TLR4 is now well accepted, but notably, many other clinically
prescribed opioids, such as oxycodone and fentanyl, also bind to TLR4 (Hutchinson et
al., 2010). In addition, the active morphine metabolite M3G binds to TLR4 with high
affinity (Hutchinson et al., 2010), causing robust activation of microglia accompanied by
cytokine release and the development of hyperalgesia (Lewis et al., 2010; Due et al.,
2012). Together, this implies that many relevant opioids may have neuro-excitatory
effects, and oppose analgesia via TLR4. Importantly, the analgesic metabolite of
morphine, M6G, does not appear to bind to TLR4 (Hutchinson et al., 2010), and is not
associated with pro-inflammatory glial activity (Carrigan and Lysle, 2001). Thus, M6G
and potential drugs that do not activate immune cells may produce greater analgesia
and represent a favorable alternative to the commonly used immune-activating opioids.

Sex differences in innate immunity
Sex differences in immunity have been well demonstrated, with females having a
more robust immune system at baseline, and more reactive immune response to
perturbation than males [for review, see (Marriott and Huet-Hudson, 2006), (GarciaSegura and Melcangi, 2006), and (Schwarz and Bilbo, 2012)]. For example, in the
peripheral immune system, female mice have higher baseline titers of immunoglobulins
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(Klein, 2000), and splenocyte blastogenic responses to T and B cell mitogens than
males (Schneider et al., 2006). Females also demonstrate increased resistance to
bacterial and parasitic infection compared with males (Klein, 2004). Sex differences in
the release of pro-inflammatory molecules (i.e. cytokines) following immune challenge
has been well documented, however, the direction of the effect is not consistent-showing increased glial activity in both males (Drew and Chavis, 2000; Aulock et al.,
2006) and females (Calippe et al., 2008; Calippe et al., 2010; Loram et al., 2012; Engler
et al., 2016). In a recent clinical study, LPS immune challenge was shown to elicit a
greater cytokine response in women that was accompanied by increased hyperalgesia
to cold/heat pain suggesting that clinical reports of sex differences in pain sensitivity
may be the result of a pro-nociceptive cytokine response that is potentiated in women
(Karshikoff et al., 2015).
Although increased immune responsivity in females is thought to be
neuroprotective, over-activation of the immune system can be pathological (Streit et al.,
2004). Females demonstrate increased inflammation and hyperalgesia in response to
immune challenge compared with males (Cook and Nickerson, 2005), which may make
females more susceptible to long-term effects of inflammation than their male
counterparts (LaPrairie and Murphy, 2007). Exaggerated inflammatory responses may
also underlie the increased prevalence of auto-immune disorders (Whitacre, 2001;
Cooper and Stroehla, 2003) and chronic inflammatory conditions observed in females.
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Dissertation aims
Previous research has investigated various factors potentially driving sex differences
in morphine analgesia, with few conclusive results to a single underlying mechanism.
Previous work from our lab demonstrates that males have more MOR in the vlPAG
(Loyd et al., 2008a) and respond more robustly to morphine agonism than females
(Zubieta et al., 2002; Loyd and Murphy, 2006, 2009); however, female analgesia
appears to have a limited relation with MOR density (Loyd et al., 2008a). This suggests
that despite physiological differences in MOR, additional or parallel underlying
mechanisms should be considered.
Given robust sex differences in immune function, and known links between
immune function and morphine efficacy, we suggest that immune modulation is a likely
novel mechanism that may be decreasing analgesic efficacy of morphine in females.
See summary Figure 1.4.1. Thus, we propose our overarching hypothesis that sex
differences in the analgesic effects of morphine are due to sexually dimorphic
responses of vlPAG microglia. Specifically, we hypothesize that females have
increased activation of microglia compared with males, thus the analgesic efficacy of
morphine is decreased to a greater degree in females. In addition, we hypothesize that
sex differences in morphine pharmacokinetics exacerbate this effect via increased M3G
binding to TLR4 (and subsequently increased glial reactivity) in females. We will test
these hypotheses in two specific aims:

Specific Aim 1: Characterize vlPAG microglia activity in males and females and
establish the role of TLR in mediating the sexually dimorphic effects of morphine.
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Despite evidence of sex-specific responses to immune challenge (Calippe et al., 2008;
Calippe et al., 2010), and a well-established relationship between immune activation
and pain (Watkins et al., 2007), TLR4-mediated glial activity has not been examined in
any brain region involved in pain processing in females, and the contribution of TLR4 to
morphine efficacy in females remains to be tested. Our previous studies demonstrate
that TLR4 signaling within the PAG modulates morphine analgesia in male rats (Eidson
and Murphy, 2013b), however, no studies have examined the role of PAG TLR4 in
females. This aim will 1) examine sex differences in distribution and activation of vlPAG
microglia using behavioral, anatomical, and molecular techniques at baseline or
following immune activation by either the TLR4 agonist LPS, or morphine. Furthermore,
2) we will demonstrate a mechanistic role of PAG microglia in modulating morphine
efficacy in males and females using site-specific injections of a TLR4 agonist and
antagonist to examine the sufficiency and necessity of vlPAG TLR4 to produce sex
differences in morphine analgesia.

Specific Aim 2: Investigate a pharmacokinetic mechanism involved in the
sexually dimorphic activation of microglia. Morphine is converted into two active
glucuronides: M3G and M6G. M6G binds to MOR and is a potent analgesic, while M3G
binds to TLR4 with high affinity to activate glia, thus opposing the analgesic effects of
morphine and M6G. In rats, M3G serum concentrations are ~2 times higher and the
ratio of M3G to morphine is ~5.5 times higher in females than males (Baker and Ratka,
2002). Despite known sex differences in morphine metabolism, a mechanistic
investigation of morphine metabolites on microglial activation or morphine analgesia has
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never been performed. Therefore, this aim will 1) examine behavioral responses to M3G
and M6G using vlPAG site-specific injections; and 2) examine the contribution of
morphine metabolites to the activation of microglia.
These studies are the first to describe a role of microglia in producing sex
differences in morphine analgesia. Furthermore, we suggest novel methods to
improve current opioid-based pain management via inhibition of glial TLR4, and
illustrate the necessity for sex-specific research and individualized treatment
strategies for the management of pain.

Figure 1.4.1. Summary Figure Describing a Potential Mechanism Underlying Reduced Morphine Efficacy
in Females.
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Abstract
Although morphine remains the primary drug prescribed for alleviation of severe or
persistent pain, both preclinical and clinical studies have shown that females require 2-3
times more morphine than males to produce comparable levels of analgesia. In addition
to binding to the neuronal μ opioid receptor (MOR), morphine binds to the innate
immune receptor toll-like receptor 4 (TLR4) localized primarily on microglia. Morphine
action at TLR4 initiates a neuroinflammatory response that directly opposes the
analgesic effects of morphine. Here we test the hypothesis that the attenuated response
to morphine observed in females is the result of increased microglia activation in the
periaqueductal gray (PAG), a central locus mediating the antinociceptive effects of
morphine. We report that while no overall sex differences in the density of microglia
were noted within the PAG of male or female rats, microglia exhibited a more “activated”
phenotype in females at baseline, with the degree of activation a significant predictor of
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morphine ED50 values. Priming microglia with LPS induced greater microglia activation
in the PAG of females compared with males that was accompanied by increased
transcription levels of IL-1ß and a significant rightward shift in the morphine dose
response curve. Blockade of morphine binding to PAG TLR4 with (+)-naloxone
significantly potentiated morphine antinociception in females such that no sex
differences in ED50 were observed. These results demonstrate that PAG microglia are
sexually dimorphic in both basal and LPS-induced activation, and contribute to the
sexually dimorphic effects of morphine in the rat.
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Introduction
Opioid therapy remains a primary strategy for severe and chronic pain
management with 3-4% of adults in the US receiving long-term opioid therapy (Dowell
et al., 2016); however, preclinical studies using a variety of acute and persistent pain
assays have repeatedly demonstrated that morphine is more effective in males than in
females (Dawson-Basoa and Gintzler, 1993; Mogil et al., 2000; Wang et al., 2006; Craft
et al., 2008; Loyd et al., 2008a). Decreased analgesic efficacy is often countered with
dose escalation, leading to increased risk of negative side effects associated with opiate
consumption, including respiratory depression, tolerance, and overdose (Trescot et al.,
2006).
Several exogenous opioids, including morphine, bind to the myeloid
differentiation factor 2 (MD-2) co-receptor of the innate immune receptor toll-like
receptor 4 (TLR4) (Hutchinson et al., 2010). TLR4 is located primarily on microglia
(Lehnardt et al., 2002; Lehnardt et al., 2003; Jou et al., 2006; Marinelli et al., 2015) and
activation of the MD2-TLR4 complex promotes the expression of pro- and antiinflammatory compounds including cytokines (tumor necrosis factor alpha [TNF],
interleukins [IL-1β, IL-6, IL-10]), chemokines (CXCL3) and prostaglandin E2 (PGE2)
(Bonizzi and Karin, 2004; Doyle and O'Neill, 2006; Hutchinson et al., 2008c; Hutchinson
et al., 2010). Activation of TLR4 and the release of proinflammatory signaling molecules
increases neuronal excitability via upregulation of α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA) receptor (Ogoshi et al., 2005; Stellwagen et al., 2005),
downregulation of glutamate transporter (Yan et al., 2014; Eidson et al., 2016), and
decreased γ-Aminobutyric acid (GABAA) receptor expression, that together, induce
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hyperalgesia. Therefore, morphine paradoxically reduces its analgesic efficacy through
TLR4-mediated inflammation (Song and Zhao, 2001; Hutchinson et al., 2007;
Hutchinson et al., 2010; Franchi et al., 2012; Li, 2012; Wang et al., 2012; Eidson and
Murphy, 2013b, a; Eidson et al., 2016).
The ventrolateral midbrain periaqueductal gray (vlPAG) is a critical neural locus
mediating the antinociceptive effects of morphine (Morgan et al., 2005; Loyd et al.,
2007). Direct PAG administration of morphine induces long-lasting analgesia, while
identical administration of the opioid antagonist (-)-naloxone or lesions of PAG μ opioid
receptor (MOR) completely abolish the antinociceptive effects of systemic morphine
(Loyd et al., 2008a). The antinociceptive effects of intra-PAG morphine are highly sexdependent, such that in males, the half-maximal antinociceptive dose (ED50) of
morphine ranges from 1.2-1.6 µg/µl, while in females, ED50 values range from 16 to >50
µg/µl (Krzanowska and Bodnar, 1999; Loyd et al., 2008a; Bobeck et al., 2009).
MD-2 is densely expressed within the PAG, and administration of morphine
activates PAG microglia, opposing the analgesic effects of morphine and inducing
tolerance in a TLR4-dependent manner (Eidson and Murphy, 2013b, a; Eidson et al.,
2016). Similarly, blockade of PAG microglial activation in male rats via TLR4 inhibition
potentiates morphine analgesia and suppresses the development of tolerance (Eidson
and Murphy, 2013a; Eidson et al., 2016). Here, we test the hypothesis that the sexually
dimorphic effects of morphine are due to sex differences in microglia activation in the
PAG.
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Materials and methods
General methods
Subjects. Age matched (60-90 day old) intact male and normally cycling female
Sprague Dawley rats (Charles River) were used. Animals were pair-housed with the
same sex on a 12:12 h light/dark cycle (lights on at 08:00). Access to food and water
was available ad libitum throughout the experiments except during behavioral testing.
All studies were approved by the Institutional Animal Care and Use Committee at
Georgia State University, and performed in compliance with Ethical Issues of the
International Association for the Study of Pain and National Institutes of Health. All
efforts were made to reduce the number of animals used in these experiments and to
minimize pain and suffering.
Vaginal cytology. Vaginal lavages were performed daily beginning 7 days prior to
testing to confirm that all female rats were cycling normally and to record cycle stage at
the time of testing. Proestrus was identified as a predominance of nucleated epithelial
cells and estrus was identified as a predominance of cornified epithelial cells. Diestrus 1
was differentiated from Diestrus 2 by the presence of leukocytes. Rats that appeared
between phases were noted as being in the more advanced stage (Loyd et al., 2007).

Experiment 1: Influence of acute morphine administration on PAG
microglia expression and morphology
To determine if morphine activation of microglia was sexually dimorphic, male
and female rats received a single ED50 injection of (-)-morphine sulfate (5 mg/kg;
National Institute on Drug Abuse (NIDA), Bethesda, MD) or saline (1 mg/kg)
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subcutaneously (s.c.) and were sacrificed by transcardial perfusion 15, 30, or 60
minutes post-injection. An additional group of animals served as handled controls,
resulting in a total of 6-8 animals per sex per group, total number of animals 54 males,
48 females.
Immunohistochemistry. At the end of the experiment, animals were given a lethal
dose of SomnaSol® (0.5-1.0 ml/kg; i.p.) and transcardially perfused with 200-250 ml of
0.9% sodium chloride containing 2% sodium nitrite as a vasodilator followed by 300 ml
of 4% paraformaldehyde in 0.1M potassium phosphate buffered saline (KPBS). Brains
were post-fixed in 4% paraformaldehyde and KPBS for 48 hours and then placed in a
30% sucrose solution and stored at 4°C. Brains were sectioned coronally at 25 µm with
a Leica 2000R freezing microtome and stored free-floating in cryoprotectant-antifreeze
solution at -20°C. A 1:6 series through the rostrocaudal axis of each brain was
processed for ionized calcium binding adaptor molecule 1 (Iba-1) immunoreactivity
using standard immunhistochemical techniques as previously described (Loyd and
Murphy, 2006). Iba-1 was selected as it is specific to microglia and is constitutively
expressed across all stages of activation, allowing for both qualitative and quantitative
assessment in both healthy/uninjured animals as well as endotoxin- and morphinetreated animals. Briefly, sections were rinsed extensively in KPBS to remove
cryoprotectant and then incubated in a rabbit anti-Iba-1 (WAKO Chemicals, Richmond,
VA; 1:10K) primary antibody solution in KPBS containing 1.0% Triton-X for one hour at
room temperature followed by 72 hours at 4°C. After rinsing with KPBS, the tissue was
incubated for one hour in biotinylated donkey anti-rabbit IgG (Jackson Immunoresearch;
West Grove, PA, 1:600), then rinsed with KPBS and incubated for one hour in an avidin-
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biotin peroxidase complex (1:10; ABC Elite Kit, Vector Labs). After rinsing in KPBS and
sodium acetate (0.175 M; pH 6.5), microglia immunoreactivity was visualized as a black
or purple reaction product using nickel sulfate intensified 3,3′-diaminobenzidine (DAB)
solution (2mg/10ml) containing 0.08% hydrogen peroxide in sodium acetate buffer.
Following incubation in DAB, tissue was rinsed in sodium acetate buffer followed by
KPBS. Sections were then mounted out of KPBS onto gelatin-subbed slides, air-dried
and dehydrated in a series of graded alcohols. Tissue-mounted slides were then
cleared in xylene and glass cover-slipped using Permount mounting medium.
Densitometry and presentation. Levels of Iba-1 immunoreactivity in the vlPAG
were compared across sex and treatment groups using semiquantitative densitometry
as previously described (Loyd et al., 2008a; Laprairie and Murphy, 2009; Eidson and
Murphy, 2013a). Twelve-bit grayscale images were captured using QImaging Retiga
EXi CCD camera attached to a Nikon microscope and iVision Image analysis software
(BioVision Technologies). The region of interest included sections through six
representative levels of the rostrocaudal axis of the vlPAG (Bregma -6.72, -7.04, -7.64, 8.0, -8.30, -8.80), with 6-12 sections per brain as previously described (Loyd et al.,
2007). As the distribution of glial cells was bilaterally symmetrical in the vlPAG, sections
were sampled unilaterally.
Morphological Analysis of Microglia Subtype. Microglia morphology is highly
representative of functional state (Karperien et al., 2013). Microglia were sampled as
described above (2-3 representative sections of the caudal ventrolateral PAG (Bregma 7.64 to -8.3) per animal) and classified into one of three principle morphological
subtypes: “non-ramified” cells, “intermediate” cells, and “ramified” cells. Non-ramified
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cells are characterized as having a large circular or oval cell body that is either
completely amoeboid in shape or with 1 or 2 thick primary processes and no secondary
processes. Highly ramified “intermediate” cells were characterized as having many
stout, thick processes arranged in bundles around a large cell body. “Intermediate”
cells often have several thick primary processes, extending a relatively short distance
from the soma; each primary process often has many short secondary processes,
giving these cells a “bushy” appearance that are very darkly stained with Iba-1. In
contrast to non-ramified and intermediate cells, highly ramified cells have small round
cell bodies with many (generally 4-10) long, thin processes. The primary processes of
highly ramified microglia have few secondary processes, extend a large distance from
the soma, and are often lightly stained with Iba-1. Representative images of each cell
type are provided in Figure 2.2.1. Non-ramified and intermediate microglia are
considered to be “active” or “reactive”, while highly ramified microglia with thin
processes are considered to be quiescent (Frank et al., 2006; Bland et al., 2010; Colton
and Wilcock, 2010; Kettenmann et al., 2011; Karperien et al., 2013; Lenz et al., 2013).
Iba1-positive cells were counted only if the cell body and processes were completely
visible within the image. Ambiguous cells with processes extending beyond the borders
of the image, overlapping cells, and cells out of the plane of focus of the image were not
counted.

Figure 2.2.1. Microglial Subtypes.
Representative images of the three classifications of microglia based on morphology. “Non-ramified”:
round/amoeboid activated microglia; “Intermediate”: reactive microglia with numerous thick processes;
“Ramified” microglia with thin long processes. Scale bars represent 2µm in all images.
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Data Analysis. Morphological cell counts were conducted using ImageJ Cell
Counter tool by three independent investigators blind to treatment and sex of the
animal. Total number of microglia were also determined to assess changes in microglia
migration or proliferation. Morphological cell counts, and total microglia number are
presented as the mean + SEM. Statistical analyses were performed using SPSS
software (Version 21); data were analyzed using an ANOVA to determine significant
main effects of sex and treatment on microglia cell counts and morphology. Bonferroni’s
post hoc test was used to determine a priori specified specific group differences when a
significant main effect was observed. p≤0.05 was considered statistically significant.

Experiment 2: Correlation between microglia activation and morphine ED50
To determine if there was a relationship between microglia morphological
subtype and morphine ED50 values, animals (n= 15 males, 8 females) were tested using
our cumulative dosing paradigm (Morgan et al., 2006; Loyd et al., 2008a; Eidson and
Murphy, 2013a; Eidson et al., 2016). Briefly, animals received an injection of morphine
every 20 minutes, resulting in cumulative doses of 1.8, 3.2, 5.6, 8.0, 10.0, and 18
mg/kg. Control animals received repeated saline injections (1 ml/kg; s.c; n= 6 males, 7
females). Thermal nociception was assessed using the paw thermal stimulator 15
minutes after each injection (Hargreaves et al., 1988; Wang et al., 2006; Loyd et al.,
2008b; Eidson and Murphy, 2013a). Briefly, for this test, the rat is placed in a clear
Plexiglas box resting on an elevated glass plate maintained at 30°C. A radiant beam of
light is positioned under the hindpaw and the time for the rat to remove the paw from the
thermal stimulus is electronically recorded as the paw withdrawal latency (PWL) in
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seconds. A maximal PWL of 20 s was used to prevent tissue damage due to repeated
application of the noxious thermal stimulus. Animals were acclimated to the testing
apparatus 30-60 minutes per day for three consecutive days prior to the start of the
experiment and on the day of testing. All behavioral testing took place between 12:00
and 17:00 (lights on at 08:00). Temperature of the thermal stimulus was recorded
before and after each trial to maintain consistent recordings between groups and did not
exceed 64°C throughout the course of the experiments. All testing was conducted blind
with respect to group assignment. To calculate ED50, PWL data was normalized using
GraphPad PRISM software, such that each individual animal’s baseline PWL score =
0% and 20s = 100%. The normalized data was then plotted and ED50 was calculated as
the point on the X-axis that corresponds with 50% maximal PWL (Morgan et al., 2006;
Eidson and Murphy, 2013a; Eidson et al., 2016).
Immunohistochemistry. Within 60 minutes of the final morphine dose, animals
were perfused and tissue was collected for immunohistochemical analyses. Microglia
were categorized in the vlPAG as described above. To determine if morphine’s impact
on glia morphology was limited to the PAG or represented a more centralized effect,
microglia were also characterized by morphological type for the following brain regions:
rostral ventromedial medulla (RVM; Bregma -11.2:-12.2; implicated in pain modulation);
superior colliculus (Bregma -6.9:-8.2; high MOR density but not implicated in pain); and
substantia nigra (Bregma -5.0:-5.3; high levels of MOR and implicated in reward and
addiction). The medial amygdala (Bregma -2.4:-3.0) was also analyzed as this region
has a high density of microglia, but is not implicated in pain and is devoid of MOR.
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Data analysis and presentation. Morphine ED50 values were compared between
males and females using Mann Whitney U Test to confirm replication of previously
observed sex differences (Loyd et al., 2008b; Loyd et al., 2008a). Analysis of
covariation between ED50 values and microglial morphological subtype were assessed
for each sex using SPSS statistical software; p≤0.05 was considered significant.

Experiment 3: Influence of peripheral endotoxin LPS on microglia response
in the vlPAG
To determine if sex differences in microglia activation are driven by morphine or
reflected a global sex difference in activation, animals received an injection of the TLR4
agonist lipopolysaccharide (endotoxin LPS; 1 mg/kg, i.p.; Sigma; n=7 males, 6 females)
or equivolume saline (n= 7 males, 6 females). Comparable doses of peripheral LPS
have been shown in male rats to increase the proinflammatory cytokine IL-1

mRNA in

the brain (Buttini and Boddeke, 1995; Nguyen et al., 1998; Quan et al., 1998; Quan et
al., 1999) and alter microglia morphology (Buttini et al., 1996). LPS-induced febrile
responses were monitored using Thermocron iButtons (Maxim Integrated, San Jose;
model DS1921G), implanted into the abdominal cavity 7-10 days prior to testing. Body
temperature was recorded in 30-minute intervals beginning 6 hours prior to LPS.
Animals were sacrificed and transcardially perfused six hours following LPS
administration, when central cytokine mRNA levels peak (Nakamura et al., 1999; Turrin
et al., 2001; Qin et al., 2007; Czerniawski and Guzowski, 2014). Tissue was collected
and processed for visualization of microglia (Iba-1) as described above. Iba-1 levels
were analyzed for the PAG, RVM, SC, SN, and MeA. A subset of animals were
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sacrificed by decapitation and their brains flash frozen for determination of cytokine
levels using qPCR as previously described (Eidson et al., 2016).
Examination and presentation of immunomodulatory cytokines using qPCR.
Flash frozen brains were sectioned at 300 μm on a cryostat (Leica) and mounted onto
slides. One-millimeter bilateral micropunches were taken from 6 levels of the vlPAG
(Bregma -6.72, -7.04, -7.64, -8.0, -8.30, -8.80) and RNA was extracted with TRIzol (Life
Technologies; 15596026) using standard procedures, followed by the addition of
Glycoblue (Life Technologies; AM5916) for visualization. Concentrations of RNA (ng/µl)
were calculated using a NanoDrop ND-1000 Spectrophotometer (Version 3.8, Thermo
Fisher; DE). Following RNA extraction, RNA was diluted to a standard concentration
and converted to cDNA using an AMV First-Strand Synthesis Kit (Invitrogen). PCR was
performed using FastStart Essential DNA Green MasterMix (Roche) and analyzed using
a Roche LightCycler 96 and accompanying software (Version 1.1.0.1320, 2011 Roche
Diagnostics; Switzerland). Data are presented as the normalized ratio of the target
gene, with corrected amplification efficiency, relative to the GAPDH control gene. Primer
sequences can be found in Table 1.
Data Analysis. The impact of sex and treatment on microglia morphology and
cytokine mRNA levels were analyzed using an ANOVA, with Bonferroni post-hoc
analysis where appropriate. Differences between males and females were compared
using independent t-tests when k=2. Body temperature data were analyzed for
significant main effects of sex and treatment across time using a mixed model ANOVA
with Greenhouse-Geisser correction. Body temperature data are presented as the
difference between saline-treated groups at 1-hour intervals post-LPS. Density,
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morphology, and PCR data are presented as Cq means ±SEM; p≤0.05 was
considered significant.

Table 1 Chapter 2 Primer Sequences for qPCR of Inflammatory Markers
Forward
GAG GTG ACC GCA TCT TCT TG
GAPDH
Reverse
CCG ACC TTC ACC ATC TTG TC
Forward

CCC TGA AGG ATG TGA TCA TTG

Reverse

GGC AAA GGG TTT CTC CAC TT

Forward

AAG ACC CAA GCA CCT TCT TT

Reverse

AGA CAG CAC GAG GCA TTT TT

Forward

TGT ACC TTA TCT ACT CCC AGG TTC TCT

Reverse

GTG TGG GTG AGG AGC ACG TA

Forward

TGT ACC TTA TCT ACT CCC AGG TTC TCT

Reverse

GTG TGG GTG AGG AGC ACG TA

Forward

TCC CTG CAT AGA GGT ACT TC

Reverse

CAC ACC TGG ATA AAT CCA GC

IL-1β

IL-6

IL-10

TNF

TLR4

Experiment 4: Effect of TLR4 manipulation on morphine analgesia
Intra-vlPAG cannulae implantation. To determine if PAG TLR4 activation or
inhibition impacted morphine analgesia, animals were anesthetized to a deep surgical
plane with 5% isoflurane (maintained at 2–5% isoflurane throughout surgery; Henry
Schein Animal Health) and bilateral guide cannulae (22 gauge; Plastics One) aimed at
the vlPAG (anterior—posterior: 1.7 mm; mediolateral: ±0.6 mm; dorsoventral: −5.0 mm
from lambda) were implanted stereotaxically as previously described (Loyd et al.,
2008a; Eidson and Murphy, 2013a). Animals were allowed to recover a minimum of 10
days post-cannula implantation before behavioral testing. Injection cannulae were
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inserted into guide cannulae once a day for three days prior to testing to acclimate the
animals to the injection procedure and maintain cannulae patency. Animals with blocked
cannula were retained as no injection controls. No significant differences were observed
between non-injected animals (n= 2 males, 5 females) and those animals receiving
intra-PAG saline, so these groups are collapsed (data not shown).
Experiment 4.1: Effects of TLR4 agonism on morphine analgesia. On the day of
testing, male and female rats received a single intra-PAG injection of LPS (5.0 μg/0.5
μl/side; Sigma) or saline (0.5 μl/side) into the PAG. This dose has been previously
shown to increase glial activation and cytokine expression (Castano et al., 2002;
Hernandez-Romero et al., 2008; Eidson and Murphy, 2013a). One hour later, morphine
ED50 values were determined using the cumulative dosing paradigm described in
Experiment 2. A total of 4 treatment groups were generated: Saline+Saline (n=5 males,
5 females), LPS+Saline (n=5 males, 5 females), Saline+Morphine (n=8 males, 11
females), and LPS+Morphine (n=7 males, 8 females).
Experiment 4.2: Effects of TLR4 antagonism on morphine analgesia. On the day
of testing, animals received a single intra-PAG injection of (+)-naloxone (5.0 μg/0.5
μl/side; NIDA) or saline (0.5 μl/side); one hour later morphine ED50 values were
determined as described above. This dose was chosen based on our previous
experiments demonstrating inhibition of PAG microglia (Eidson and Murphy, 2013a). A
total of 4 treatment groups were generated: Saline+Saline (n=5 males, 5 females),
Naloxone+Saline (n=5 males, 5 females), Saline+Morphine (n=8 males, 11 females),
and Naloxone+Morphine (n=7 males, 9 females).
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Data analysis and presentation. At the end of the experiment, brains were
removed, flash frozen, and sectioned at 25 μm with a Leica CM3050S cryostat.
Sections from the injection site were mounted on to slides, Nissl stained, coverslipped,
and cannulae placement verified using a Nikon microscope (10X magnification).
Animals with bilateral cannulae located outside of the vlPAG (e.g., in the aqueduct or
deep mesencephalic nucleus) were considered “cannulae misses” and analyzed for
determination of site specificity.
Half-maximal antinociceptive effect (ED50) and 95% confidence intervals (CI)
were calculated from dose–response curves generated using Graph-Pad PRISM
software as described above. Repeated measures ANOVA was used to assess for
significant treatment effects, with Bonferroni’s post hoc tests where appropriate.
Cannula misses were compared to “hits” using a two-tailed Wilcoxon signed-rank test.
Values of p≤0.05 were considered statistically significant.
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Results
Experiment 1: Sex, but not morphine treatment, affects microglia activation
in the vlPAG
Male and female rats were administered morphine or saline, and microglia were
examined immunohistochemically within the caudal vlPAG at 15, 30, and 60 minutes
post-injection. A separate group of rats served as handled controls. No significant effect
of time post-injection was noted in microglia morphology for either the saline or
morphine treated groups so these data are collapsed across time. Additionally, no
significant differences were observed in total microglia cell counts in the PAG,
regardless of sex (F(1,68)=0.013, p= 0.91) or treatment (F(1,68)=0.13, p= 0.720; Figure
2.3.1a).
Overall, females had significantly more non-ramified and intermediate type
microglia in the vlPAG that was independent of treatment (F(1,76) = 13.10, p= 0.01;
Figure 2.3.1b). We next determined if the observed sex difference in percentage of
activated microglia was specific for a morphological subtype (non-ramified, intermediate
or ramified; see Figure 2.3.1). The percentage of both non-ramified (t= 3.10, p< 0.001)
and intermediate (t= 2.17, p= 0.03) microglia was significantly higher in females than
males (Figure 2.2c). Females also had significantly fewer ramified microglia than males
(t= 3.90, p< 0.001). Together, these data indicate that although there are no sex
differences in the overall number of vlPAG microglia, the ratio of non-ramified and
intermediate to ramified microglia are significantly greater in females than males,
regardless of treatment.

35

Figure 2.3.1. Sex, but Not Morphine Treatment or Time, Affects Microglia Activation in the vlPAG.
(a) No significant differences in microglia cell number were noted as a function of sex, time (collapsed) or
treatment (handled [n= 5 males, 6 females], saline [n= 15 males, 17 females], morphine [n= 22 males, 17
females]). (b) Females had significantly more non-ramified/amoeboid [NR] and intermediate [I] microglia
than males regardless of treatment (t(80)=3.90, p<0.001). As shown in the scatterplot at right, the
percentage of non-ramified/amoeboid [NR] and intermediate [I] microglia were highly variable within each
sex (line indicates median). (c) Females had significantly more non-ramified [NR] and intermediate [I], and
fewer ramified [R] microglia in the vlPAG than males.
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Experiment 2: Microglial activation in the PAG correlates with morphine
ED50.
PAG or spinal cord activation of microglia has been shown to oppose morphine
analgesia (Watkins et al., 2005; Hutchinson et al., 2010; Eidson and Murphy, 2013b, a);
therefore, we next examined the degree of association between morphine ED50 values
and PAG microglia morphology for males and females. Animals were administered
cumulative doses of morphine and sacrificed within sixty minutes of the final injection of
morphine; microglia morphology was determined immunohistochemically. Consistent
with our previous studies (Loyd et al., 2008b; Loyd et al., 2008a), ED50 values were
significantly higher in females than males (female, 8.69 vs. male, 6.01 mg/kg; U = 30.5,
p= 0.028), and no relationship was observed between ED50 and female estrus cycle (r=
0.19, p= 0.19). Morphine ED50 values were significantly correlated with the percentage
of non-ramified and intermediate microglia, morphologies typical of “activated” microglia,
in the vlPAG in both males (r=0.58, p=0.02) and females (r=0.68, p=0.047; Figure
2.3.2a). Further analysis by microglia morphological subtype showed no significant
correlation for non-ramified microglia and morphine ED50 in males (r= 0.47, p= 0.051) or
females (r= 0.32, p= 0.24). Intermediate microglia correlated significantly with ED50 in
females (r= 0.679, p= 0.047) but not males (r= 0.316, p= 0.15), and ramified microglia
negatively correlated with ED50 in both males (r= -0.58, p= 0.02) and females (r= -0.68,
p= 0.047; Figure 2.3.2b). Together, these data show sex-specific positive correlations
between morphine ED50 and percentage of activated microglia, and reciprocal negative
correlations with morphine ED50 and ramified microglia, such that as the percent of
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ramified microglia decreases, morphine ED50 increases (i.e. morphine is less
efficacious).
We next determined if the relationship between microglia morphology and
morphine ED50 values was specific to the PAG, or extended to regions also implicated
in pain (RVM), and/or regions with high levels of MOR (SN, SC) or a high density of
microglia (MeA). For females, no significant correlation between morphine ED 50 and the
percentage of non-ramified and intermediate microglia were observed in RVM (r= 0.21,
p= 0.32), amygdala (r= 0.48, p= 0.12), superior colliculus (r= -0.05, p= 0.46), or
substantia nigra (r= 0.09, p= 0.44). Similarly, in males, no significant correlations were
observed in the RVM (r= -0.13, p= 0.35), amygdala (r= 0.23, p= 0.24), or substantia
nigra (r= 0.32, p= 0.20). However, significant correlations between morphine ED50 and
percentage of non-ramified and intermediate microglia were noted in superior colliculus
of male rats (r= 0.53, p= 0.05; Figure 2.3.2c-g).
Similar to what was observed for the PAG, no significant differences were
observed in the total number of microglia in any of the brain regions examined (F (3,28)=
0.152, p= 0.93; data not shown), indicating that the difference in the number of activated
cells between males and females is not due to increased proliferation or migration of
activated microglia. Rather, these data indicate that morphine ED50 positively correlates
with the overall percent of non-ramified and intermediate microglia, states typical of
activation, in the PAG in males and females, with sex-specific differences in correlations
noted for the superior colliculus.
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Figure 2.3.2. Percent Activated Microglia Correlate with Morphine Effective Dose.
Bivariate correlations of morphine ED50 for the percentage of (a) total non-ramified and intermediate
microglia and (b) by morphological subtype within the PAG. Degree of relatedness for morphine ED 50 and
microglia morphology are also shown for the (c) amygdala, (d) rostral ventral medulla, (e) superior
colliculus, and f) substantia nigra. n= 15 males, 8 females.
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Experiment 3a: Immune Challenge Activates vlPAG Microglia to a Greater
Extent in Females than in Males
The results from the above experiment show that although there were
significantly more microglia with a non-ramified or intermediate morphology in females
than males, these microglia were unaffected by morphine treatment. Therefore, we
next tested if administration of LPS, a TLR4 agonist, activated vlPAG microglia in a sexdependent manner. Peripheral administration of LPS induced a significant increase in
the percent of non-ramified and intermediate microglia in the vlPAG of females (19%),
but not males (12%; Figure 2.3.3a); significant main effect of sex (F(1,22)=18.26, p<
0.001) and treatment (F(1,22)= 11.84, p< 0.001). Similar to what was noted in Experiment
1, females had more non-ramified and intermediate microglia in the PAG at baseline
(p=0.03).
Analysis of microglia by morphological subtype showed a significant main effect
of both sex (F(2, 44)= 13.14, p= 0.001) and treatment (F(2,44) = 6.44, p= 0.001) on
microglia morphology and no interaction (F(2,44)= 0.55, p= 0.58). Specifically, saline
treated females had significantly more intermediate (t= 2.43, p= 0.05), and significantly
fewer ramified (t= 2.83, p= 0.03) microglia than saline males. Similarly, LPS-treated
females have significantly more intermediate (t= 2.95, p= 0.01), and significantly fewer
ramified (t= 3.10, p= 0.01) microglia than LPS males (Figure 2.3.3b), suggesting a more
“activated” morphological state in females. The observed sex difference in microglia
morphology in the PAG was not accompanied by differences in sickness behaviors as
no sex differences in core body temperature were observed in animals treated with LPS
(F(1,13)=2.22, p= 0.16; Figure 2.3.3d). These data suggest that in females, PAG microglia
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may be more responsive to TLR4 activation (i.e. lower threshold) than their male
counterpart.
No significant main effects of sex on total number of non-ramified and
intermediate microglia were observed in any other brain region examined (Figure
2.3.3e). In contrast to what was noted with morphine, main effects of LPS-treatment
were observed in several brain regions, including the superior colliculus (F(1,20)=10.862,
p< 0.001) in males (p= 0.01) but not females (p=0.08), and the RVM (F(1,15)=5.76, p=
0.03) in males (p= 0.03) but not females (p= 0.32). No significant main effects of LPS
treatment were observed in the amygdala or substantia nigra, and no interaction effects
were observed in any brain region tested. Finally, no significant differences were
observed in the total number of microglia in any brain regions examined (data not
shown).
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Figure 2.3.3. Treatment with TLR4 Agonist Lipopolysaccharide Increases Microglia Activation in Females.
(a) LPS induces greater proportions of non-ramified/amoeboid [NR] and intermediate [I] microglia in the
PAG of females than males. (b) LPS-treated females had a higher percent of intermediate (I) microglia in
the vlPAG than saline-treated females and show decreased percent of ramified (R) microglia compared
with all other groups. (c) Representative images of microglia in the vlPAG of an LPS-treated male and
female. Note that females have a greater density of non-ramified and intermediate microglia than males.
Scale bar = 5µm. (d) No sex differences in febrile response were noted following LPS administration. (e)
Percentage of non-ramified and intermediate microglia for males and females following saline or LPS
administration. LPS-induced increases in activated microglia were region- and sex-dependent. Endotoxin
LPS, n=7 males, 6 females; saline, n= 7 males, 6 females.
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Experiment 3b: Immune challenge induces greater cytokine expression in
the vlPAG of females
To determine if the observed sex differences in PAG microglia morphology was
accompanied by sex-specific differences in proinflammatory cytokine transcription,
qPCR was used to quantify PAG mRNA levels of pro-inflammatory TNF, IL-1β, IL-6, and
anti-inflammatory IL-10 (Figure 2.3.4). LPS induced a significant increase in vlPAG TNF
transcription in both males (p < 0.001) and females (p < 0.001) compared with saline
controls (F(1,42)= 50.72, p< 0.001). LPS treatment also induced in a significant increase
in IL-1β transcription in females (p<0.001) and males (p<0.001); significant main effect
of treatment (F(1,38) = 47.08, p= 0.00). Notably, IL-1β levels were significantly higher in
LPS treated females than males (p=0.03). LPS did not significantly change IL-6 in either
sex (F(1,34)= 0.19, p= 0.67). PAG transcription of the anti-inflammatory cytokine IL-10
was significantly higher in males than in females (F(1,44)= 14.99, p< 0.001). LPS induced
a significant decrease in IL-10 mRNA in females (t=3.33, p< 0.001) but not males (t=0.19, p=0.86; Figure 2.3.4e). Together, these data demonstrate that PAG TLR4
activation induces an exaggerated pro-inflammatory response and a reduced antiinflammatory response in females compared with males. Furthermore, these data
support our immunohistochemical studies demonstrating that changes in microglial
morphology are accompanied by measurable changes in pro-inflammatory cytokine
mRNA.
We also examined LPS induced changes in PAG TLR4 transcription. LPS
administration increased TLR4 transcription by 67% in females and 39% in males,
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however these differences were not statistically significant: treatment, F(1,40)= 2.37, p=
0.13; sex, F(1,40)= 2.37, p= 0.13.

Figure 2.3.4. LPS-induced Changes in Cytokine and TLR4 Transcription in the vlPAG of Males and
Females.
Peripheral administration of LPS increased the transcription of (a) TNF and (b) IL-1β in the vlPAG. No
change in IL-6 was noted (c). Transcription of the anti-inflammatory cytokine IL-10 significantly decreased
in females following LPS (d). No differences in TLR4 transcription (e) were noted for sex or treatment.
Endotoxin LPS, n=5 males, 5 females; saline, n= 3 males, 3 females.
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Experiment 4. Manipulation of PAG TLR4 signaling has sex-dependent
effects on morphine ED50 values
Our previous studies established a direct link between microglia activation and
morphine efficacy, such that site specific administration of the TLR4 agonist LPS
resulted in a significant reduction in morphine efficacy (as indicated by a rightward shift
in the morphine dose-response curve (Eidson and Murphy, 2013a). Given the results of
the present experiments demonstrating that females show more non-ramified and
intermediate morphologies than males, we next examined if this sex difference in
microglia morphology would result in a sexually dimorphic shift in morphine ED50. In
particular, we tested if activation of vlPAG TLR4 via site specific administration of the
endotoxin LPS would result in a larger rightward shift in the morphine dose-response
curve in females compared with males. We further examined if blockade of TLR4
signaling with (+)-naloxone would result in a greater leftward shift of the morphine doseresponse curve in females, indicative of potentiation of morphine antinociception in
females.
Intra-PAG administration of LPS resulted in a significant decrease in morphine
antinociception in both males and females, as indicated by a significant rightward shift in
the morphine ED50 dose-response curve (F(5,30) = 18.01, p< 0.0001; Figure 2.3.5a). LPS
increased male ED50 values from 3.04 to 10.69 mg/kg, a 3.5 fold difference, p< 0.001;
female ED50 values increased from 7.9 to 20.61 mg/kg, a 2.6 fold difference, p< 0.05.
ED50 values were approximately two-fold higher in LPS+Morphine females than males
(20.61 in females vs. 10.69 mg/kg in males; p> 0.05). Remarkably, following LPS
priming, 6/8 females continued to respond at baseline levels following morphine
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administration at 10 mg/kg; 2 of those 6 females responded near baseline following the
18 mg/kg dose. Indeed, females in the LPS+Morphine treated groups were not
significantly different from saline control females that received no morphine
(Saline+Saline females; p>0.05), indicating that LPS pre-treatment completely
abolished the antinociceptive effects of morphine in a subset of females. No differences
in response latencies were observed between LPS+Morphine males and
Saline+Morphine females (p> 0.05), indicating that LPS activation of microglia reduced
males to ‘female-typical’ levels of analgesia.
No sex differences were observed between Saline+Saline treated males and
females (p> 0.05), and no significant differences were observed between LPS+Saline
and Saline+Saline males (p> 0.05) or females (p>0.05), indicating LPS administration
alone had no effect on basal PWL, consistent with what we have previously observed
(Eidson and Murphy, 2013a). Together, these results indicate that microglia activation
with LPS significantly decreases, or completely abolishes (in 33% of females), the
antinociceptive effects of morphine.
We next determined if blocking microglia activation with the TLR4-specific
antagonist (+)-naloxone potentiated morphine analgesia in a sex-dependent manner. In
animals treated with morphine, intra-PAG administration of (+)-naloxone significantly
increased antinociception in females, but not males, as indicated by a leftward shift in
the morphine dose response curve (F(3,18) = 13.67, p<0.0001; Figure 2.3.5b).
Specifically, ED50 values for females treated with (+)-naloxone decreased from 7.9
mg/kg to 3.16 mg/kg (p< 0.001), a 2.5-fold reduction in ED50. Importantly, ED50 values
for (+)-naloxone+Morphine treated females are not significantly different from
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Saline+Morphine treated males (p> 0.05), indicating that blocking microglia activation
within the vlPAG completely abolishes sex differences in morphine analgesia. A
moderate, but significant, increase in morphine ED50 was observed in males receiving
(+)-naloxone+Morphine compared with Saline+Morphine males (ED50 increased from
3.04 mg/kg vs. 5.25 mg/kg; p< 0.05).
No sex differences between Saline+Saline treated males and females (p> 0.05)
was observed. In addition, we observed no significant differences between (+)naloxone+Saline and Saline+Saline controls in males (p> 0.05) or females (p> 0.05)
indicating (+)-naloxone administration has no effect on basal nociceptive thresholds.
The effects of (+)-naloxone on morphine analgesia are site-specific; male and female
animals receiving (+)-naloxone outside the PAG showed significantly lower morphine
antinociception relative to animals that received (+)-naloxone within the PAG (F(3,18) =
15.17, p<0.001; data not shown). Together, these data indicate inhibition of vlPAG
microglia activity with the TLR4-specific antagonist (+)-naloxone is sufficient to reverse
sex differences in morphine analgesia.
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Figure 2.3.5. Pharmacological Blockade or Activation of vlPAG Microglia has a Sex-dependent Impact
on Morphine Antinociception.
(a) LPS-induced activation of vlPAG microglia significantly attenuates the antinociceptive effects of
morphine in both males and females, as indicated by a significant rightward shift in the morphine dose
response curve. Saline+Saline (n=5 males, 5 females), LPS+Saline (n=5 males, 5 females),
Saline+Morphine (n=8 males, 11 females), and LPS+Morphine (n=7 males, 8 females). (b) In contrast,
inhibition of TLR4 via intra-vlPAG (+)-naloxone results in a significant leftward shift in morphine doseresponse curves in females, such that (+)-naloxone + Morphine-treated females are not significantly
different from Saline + Morphine-treated males. Naloxone+Saline (n=5 males, 5 females),
Naloxone+Morphine (n=7 males, 9 females).
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Discussion
Here we test the hypothesis that sex differences in vlPAG microglia contribute to
the sexually dimorphic effects of morphine. We report that although no sex differences
in overall number or density of microglia were noted for the vlPAG at baseline, the
percentage of non-ramified and intermediate versus “ramified” microglia were
significantly higher in females than males, suggesting that females have a more
'activated” microglial state within the vlPAG. Consistent with our previous studies,
morphine ED50 values were significantly higher in females (Loyd et al., 2008b; Loyd et
al., 2008a) , and a significant relationship was observed between morphine potency and
percentage of reactive “intermediate” microglia in females, but not males. Although
acute morphine treatment did not change microglia morphology in either sex,
administration of the glial TLR4 agonist LPS increased the percentage of non-ramified
and intermediate microglia in the vlPAG of females to a greater degree than males, an
effect that was independent of febrile response. The LPS induced increases in microglia
activation in females was accompanied by significantly increased proinflammatory IL-1β
transcription and decreased anti-inflammatory IL-10 transcription. We further show that
priming microglia with LPS significantly attenuates morphine analgesia in both sexes,
and completely abolishes the antinociceptive response to morphine in a subset of
females. Similarly, inhibition of vlPAG microglia with the TLR4 antagonist (+)-naloxone
significantly potentiates morphine analgesia in females, but not males, abolishing the
sex difference in opiate response. Together, these data indicate that vlPAG microglia
are innately different in males and females in terms of their morphological state (both
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basal and following immune activation with LPS), and implicate TLR4 in the attenuated
response to morphine observed in females.
These studies are the first to implicate vlPAG microglial TLR4 in sex differences
in morphine analgesia, and suggest that increased activation of vlPAG microglia
contribute to the attenuated response to morphine observed in females. Importantly,
these experiments establish that inhibition of vlPAG TLR4 in females reverses the
observed sex differences in morphine analgesia. Together, these data suggest novel
methods to improve current morphine-based pain management via inhibition of TLR4,
and illustrate the necessity for sex-specific research and individualized treatment of pain
in men and women.
Sex differences in morphine analgesia and TLR4
Preclinical studies utilizing orofacial, somatosensory or visceral pain assays
typically report that morphine produces a significantly greater degree of analgesia in
males versus females (Craft, 2003; Craft et al., 2004; Ji et al., 2006; Wang et al., 2006;
Loyd et al., 2008a). Consistent with the present results, these studies also report
morphine ED50 values that are 2-fold higher in females than in males. The present
studies demonstrate that sex differences in PAG microglia, and in particular TLR4
signaling, contribute to the dimorphic response to morphine. TLR4 signaling has been
previously shown to modulate morphine action in males (Tanga et al., 2005; Hutchinson
et al., 2007; Hutchinson et al., 2008b; Hutchinson et al., 2008a), such that TLR4
activation with LPS reduces morphine efficacy (Johnston and Westbrook, 2005). The
present studies confirm these previous findings in males, and further demonstrate that
initiation of TLR4 signaling significantly, and almost completely, attenuates morphine
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analgesia in females. In addition, blockade of vlPAG TLR4 increases the analgesic
efficacy of morphine in females (2.5-fold reduction in morphine ED50), reversing the
observed sex difference in morphine response.
Several factors have been shown to contribute to the sexually dimorphic
response to morphine. Interestingly, these factors are also heavily impacted by
microglia. For example, blockade of N-methyl-d-aspartate (NMDA) signaling inhibits
microglia activation (Thomas and Kuhn, 2005; Murugan et al., 2011) and enhances the
antinociceptive effects of morphine to a greater degree in male than female rats
(Holtman et al., 2003). Sex differences in MOR expression and signaling in the PAG
(Bernal et al., 2007; Loyd et al., 2008a), as well as spinal MOR:KOR dimerization
(Chakrabarti et al., 2010), have also been shown to contribute to the dimorphic effects
of morphine. MOR expression is rapidly upregulated following peripheral inflammation
and cytokine release in male rats (Ji et al., 1995; Mousa, 2003; Puehler et al., 2004),
likely a homeostatic response that counteracts the excitatory effects of glial activation
and thereby increases opioid efficacy. Interestingly, no change in MOR expression is
noted in female rats following peripheral inflammation (Zhang et al., 2014), which may
also contribute to the reduced antinociceptive effects of morphine observed in persistent
pain assays (Cook and Nickerson, 2005; Loyd and Murphy, 2006; Wang et al., 2006;
Murphy et al., 2009). We speculate that NMDAR and MOR activity represent
downstream or parallel targets of microglia activation, and may explain the existence of
multiple mechanisms underlying the sexually dimorphic response to morphine.
Sex-specific differences in TLR4 modulation of pain have been previously
reported (Sorge et al., 2011; Sorge et al., 2015b). For example, in mice, inhibition or
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transient depletion of spinal microglia reverses mechanical allodynia induced by spared
nerve injury in males, but not females, suggesting that spinally-mediated chronic pain in
females is maintained in a non-TLR dependent manner (e.g. an adaptive immunedependent response) (Sorge et al., 2015a). In the present study, chronic pain was not
induced; rather, LPS was administered to activate microglia in a TLR4-dependent
manner. Sex-specific effects of TLR4 activity exemplify the need to consider both sexes
when studying immune responses and the development of drugs impacting immune
signaling. As TLR4 has also been shown to mediate the rewarding effects of morphine
(Hutchinson et al., 2012) and the development of tolerance to morphine (Eidson and
Murphy, 2013b; Eidson et al., 2016), sex differences in TLR4 signaling may have broad
implications for the treatment of chronic pain in men and women.
Sex differences in innate immune function
In the present study, we show that female rats have significantly more “activated”
microglia in the PAG than males at baseline, a difference that is potentiated following
systemic LPS treatment. This finding suggests that females have a lower threshold for
activation and/or launch a more robust proinflammatory response compared with males.
Indeed, females of many species launch a more robust immune response than males
(Gaillard and Spinedi, 1998; Klein, 2000; Schwarz and Bilbo, 2012). For example, in the
peripheral immune system, female mice have higher titers of immunoglobulins (Klein,
2000) and splenocyte blastogenic responses to T and B cell mitogens than males
(Schneider et al., 2006). Females often present with greater levels of pro-inflammatory
markers following immune challenge (Tonelli et al., 2008; Bollinger et al., 2016;
Morrison and Filosa, 2016). Interestingly, despite increases in PAG microglia activation
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and IL-1β release in response to LPS immune challenge in females, we observed no
sex differences in LPS-induced febrile response. However, IL-6, which correlates most
closely with changes in body temperature (LeMay et al., 1990; Roth et al., 1993; Roth
and De Souza, 2001), was not different in males and females, and may account for the
lack of observed sex difference in fever response.
The present experiments used normally cycling female rats. Estrus cycle was
monitored, but not controlled or manipulated, to demonstrate physiologically relevant
changes in microglia activation as a function of estrus cycle. No significant effect of
estrus cycle was observed in any of the present experiments. Immunomodulatory
effects of sex hormones, specifically estradiol, have been shown to alter cytokine
release and microglial activation in a concentration-, age-, and duration-dependent
manner. For example, uterine TNF, IL-1β, and IL-6 levels increase during proestrus and
estrus in rats (De et al., 1992), when estradiol is high. This coincides with our previous
data demonstrating that morphine is least effective in reducing nociception during
proestrus (Loyd et al., 2008a). Historically, estradiol is thought to be neuroprotective,
but these effects may be biphasic (Whitacre et al., 1999) such that high levels of
estradiol decrease inflammatory markers and attenuate the inflammatory response to
LPS (Dimayuga et al., 2005), while low doses, comparable to normal circulating levels,
increase concentrations of proinflammatory cytokines (Correale et al., 1998).
Furthermore, chronic but not acute estradiol administration increases pro-inflammatory
responses in peripheral immune cells of females compared with males (Calippe et al.,
2008; Calippe et al., 2010), and potentiates LPS-evoked TLR4 immune responses in
vitro (Loram et al., 2012). Consistent with clinical research demonstrating that women
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have a much higher incidence rate of autoimmune disorders and chronic inflammatory
conditions such as migraine (Buse et al., 2013), osteo- and rheumatoid arthritis
(Whitacre, 2001) compared with men, these results suggest that women may have
increased susceptibility to immune challenge and are at a greater risk for developing
inflammatory pathologies than men.
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OPIOID METABOLITES SEX-DEPENDENTLY IMPACT MORPHINE ANALGESIA
IN THE RAT
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Abstract
Preclinical studies report that the effective dose for morphine is approximately 2fold higher in females than males. Following systemic morphine administration,
morphine is metabolized via Phase II glucuronidation in the liver and brain into two
active metabolites: morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G),
each possessing distinct pharmacological profiles. M6G binds to μ opioid receptors and
acts as a potent analgesic. In contrast, M3G binds to TLR4, initiating a
neuroinflammatory response that directly opposes the analgesic effects of morphine
and M6G. M3G serum concentrations are 2-fold higher in females than males, however,
sex-specific effects of morphine metabolites on analgesia and glial activation in vivo
remain unknown. The present studies test the hypothesis that increased M3G, and
subsequent TLR4-mediated activation of glia, is a primary mechanism driving the
attenuated response to morphine in females. We demonstrate that intra-PAG M6G
resulted in a greater analgesic response in females, with females requiring less than
half the dose to achieve maximal analgesia relative to males. In contrast, intra-PAG
M3G administration significantly attenuated the analgesic effects of systemic morphine
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in males only, increasing the effective dose of morphine two-fold (5.0 vs 10.3 mg/kg).
Together, these data implicate sex differences in morphine metabolism, specifically
M3G, as a contributing factor in the attenuated response to morphine observed in
females.
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Introduction
Opioids such as morphine are widely used for the treatment of severe pain, with
3-5% of adults in the US receiving long-term opioid therapy (Dowell et al., 2016).
Preclinical studies using both acute and chronic pain assays report that morphine is less
effective in females than in males (Dawson-Basoa and Gintzler, 1993; Mogil et al.,
2000; Craft et al., 2008; Loyd et al., 2008a). Indeed, greater antinociception is observed
in male rats for almost every opioid tested (Barrett et al., 2002; Terner et al., 2003;
Stoffel et al., 2005; Peckham and Traynor, 2006; Bai et al., 2015).
The midbrain periaqueductal gray (PAG) is a key neural locus for opioid action
(Morgan et al., 2005; Loyd et al., 2007). Direct PAG administration of morphine induces
long-lasting analgesia, while intra-PAG administration of the opioid antagonist (-)naloxone or lesions of PAG μ opioid receptor (MOR) completely abolish the
antinociceptive effects of systemic morphine (Loyd et al., 2008a). Sex differences are
also evident following intra-PAG administration of morphine, with the half-maximal
antinociceptive dose (ED50) in males ranging from 1.2-1.6 µg/µl, while in females ED50
values range from 16 to >50 µg/µl (Krzanowska and Bodnar, 1999; Loyd et al., 2008a;
Bobeck et al., 2009).
Recent data suggest that the innate immune receptor, toll-like receptor 4 (TLR4),
contributes to the sexually dimorphic effects of morphine (Doyle et al., 2017). Many
opioids, including morphine, bind to myeloid differentiation factor 2 (MD-2), a coreceptor of TLR4, located on glial cells (Hutchinson et al., 2010). Although the classical
μ opioid receptor (MOR) binds only the (-)-stereoisomer of opioids, TLR4 binds opioids
in a non-stereoselective manner (i.e., both the (-) and (+) isomers of opioid ligands
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modulate glial signaling) (Hutchinson et al., 2010). TLR4 activation initiates an
inflammatory response that is characterized by the release of inflammatory compounds
including cytokines (tumor necrosis factor alpha [TNF], interleukins [IL-1β, IL-6, IL-10]),
chemokines (CXCL3) and prostaglandin E2 (PGE2) (Bonizzi and Karin, 2004; Doyle
and O'Neill, 2006; Hutchinson et al., 2008c; Hutchinson et al., 2010). These
inflammatory factors increase neuronal excitability, resulting in hyperalgesia (Ogoshi et
al., 2005; Stellwagen et al., 2005; Yan et al., 2014; Eidson et al., 2016) and
paradoxically reducing the analgesic efficacy of morphine (Hutchinson et al., 2007;
Hutchinson et al., 2010; Franchi et al., 2012; Li, 2012; Eidson et al., 2016). Our previous
research demonstrates that inhibition of TLR4 in the vlPAG with the TLR4-specific
antagonist (+)-naloxone potentiates analgesia in females and abolishes the sex
difference in morphine response (Doyle et al., 2017).
Recent studies suggest that morphine’s primary metabolites contribute
significantly to its immunomodulatory effects (Lewis et al., 2010; Grace et al., 2014).
Following administration, ~90% of morphine is metabolized primarily in the liver
(Coffman et al., 1997), as well as peripheral macrophages (Tochigi et al., 2005) and
brain microglia (Togna et al., 2013), to form two active glucuronide metabolites:
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), each with distinct
pharmacological properties (Coughtrie et al., 1989; Christrup, 1997). M6G binds to
MOR with high affinity, and is a potent analgesic (Abbott and Palmour, 1988; Wittwer
and Kern, 2006). M3G, on the other hand, does not bind to MOR and does not produce
analgesia (Loser et al., 1996). Rather, M3G binds with high affinity to TLR4 (Lewis et
al., 2010; Due et al., 2012) to upregulate pro-inflammatory IL-1 in vitro, induce allodynia
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and hyperalgesia, and actively opposes the analgesic effects of morphine and M6G
(Smith et al., 1990; Ekblom et al., 1993; Bartlett et al., 1994; Angst and Clark, 2006;
Juni et al., 2006; Lewis et al., 2010). Importantly, unlike the vast majority of opioids,
M6G does not bind to TLR4 and is not associated with a pro-inflammatory response
(Carrigan and Lysle, 2001; Hutchinson et al., 2010).
Several studies in rats have observed sex differences in morphine metabolism,
such that morphine administration results in approximately two-times greater
concentrations of M3G in the plasma of females compared with males (Baker and
Ratka, 2002; South et al., 2009). Though M3G concentrations are higher in females,
there is no direct evidence that the increased M3G:M6G ratio contribute to the reduced
efficacy of morphine observed in females. The present studies test the hypothesis that
M3G specifically contributes to the observed sex differences in morphine
antinociception by activating TLR4 and opposing morphine analgesia to a greater
degree in females. Most importantly, the present studies investigate whether MOR
activation with M6G, in the absence of morphine/M3G-induced glial activation, ultimately
leads to equipotent analgesia in both males and females.
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Materials and methods
General methods
Subjects. Age and weight matched (60-90 day old; 250-400g) intact male and
normally cycling female Sprague Dawley rats (Charles River) were used. Animals were
pair-housed with the same sex on a 12:12 h light/dark cycle (lights on at 08:00). Access
to food and water was available ad libitum throughout the experiments except during
behavioral testing. All studies were approved by the Institutional Animal Care and Use
Committee at Georgia State University, and performed in compliance with Ethical
Issues of the International Association for the Study of Pain and National Institutes of
Health. All efforts were made to reduce the number of animals used in these
experiments and to minimize pain and suffering.
Vaginal Cytology. Vaginal lavages were performed daily beginning 7 days prior to
testing to confirm that all female rats were cycling normally and to record cycle stage at
the time of testing (Loyd et al., 2007).
Intra-vlPAG cannulae implantation and injections. Animals were anesthetized to
a deep surgical plane with 5% isoflurane (maintained at 2–5% isoflurane throughout
surgery; Henry Schein Animal Health) and bilateral guide cannulae (22 gauge; Plastics
One) aimed at the vlPAG (anterior—posterior: 1.7 mm; mediolateral: ±0.6 mm;
dorsoventral: −5.0 mm from lambda) were implanted stereotaxically and maintained as
previously described (Loyd et al., 2008a; Eidson and Murphy, 2013a). Animals were
allowed to recover 11-14 days post-cannula implantation before behavioral testing.
Animals with blocked cannula were retained as no injection controls. No significant
differences were observed between non-injected animals and those animals receiving
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intra-PAG saline, so these groups are collapsed (data not shown). Animals with bilateral
cannulae located outside of the vlPAG (e.g., in the aqueduct or deep mesencephalic
nucleus) were considered “cannula misses” and were not included in any analyses.
Behavioral Testing and data presentation. Thermal nociception was assessed
using the paw thermal stimulator (Hargreaves et al., 1988; Wang et al., 2006; Loyd et
al., 2008b; Eidson and Murphy, 2013a; Doyle et al., 2017). Briefly, for this test, the rat is
placed in a clear Plexiglas box resting on an elevated glass plate maintained at 30°C. A
radiant beam of light is positioned under the hindpaw and the time for the rat to remove
the paw from the thermal stimulus is electronically recorded as the paw withdrawal
latency (PWL) in seconds. A maximal PWL of 20 s was used to prevent tissue damage
due to repeated application of the noxious thermal stimulus. Animals were acclimated to
the testing apparatus 30-60 minutes per day for three consecutive days prior to the start
of the experiment and on the day of testing. All behavioral testing took place between
10:00 and 15:00 (lights on at 08:00). Temperature of the thermal stimulus was recorded
before and after each trial to maintain consistent recordings between groups and did not
exceed a range of 60-64°C throughout the course of the experiments. All testing was
conducted blind with respect to group assignment. Data were normalized to the percent
maximum possible effect (%MPE) using the following formula:
%𝑀𝑃𝐸 =

𝑃𝑎𝑤 𝑊𝑖𝑡ℎ𝑑𝑟𝑎𝑤𝑎𝑙 𝐿𝑎𝑡𝑒𝑛𝑐𝑦
(100)
20 𝑠

Tissue analysis and data presentation of qPCR. At the end of each experiment,
brains were removed, flash frozen, and sectioned at 300 μm with a Leica CM3050S
cryostat and mounted on to sterile slides. One-millimeter bilateral micropunches were
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taken from 6 levels of the vlPAG (Bregma -6.72, -7.04, -7.64, -8.0, -8.30, -8.80) and
RNA was extracted with TRIzol (Life Technologies; 15596026) using standard
procedures, followed by the addition of Glycoblue (Life Technologies; AM5916) for
visualization. Concentrations of RNA (ng/µl) were calculated using a NanoDrop ND1000 Spectrophotometer (Version 3.8, Thermo Fisher; DE). Following RNA extraction,
RNA was diluted to a standard concentration and converted to cDNA using an AMV
First-Strand Synthesis Kit (Invitrogen). PCR was performed using FastStart Essential
DNA Green MasterMix (Roche) and analyzed using a Roche LightCycler 96 and
accompanying software (Version 1.1.0.1320, 2011 Roche Diagnostics; Switzerland).
Primer sequences can be found in Table 1.
qPCR data are presented as the normalized ratio of the target gene relative to
the GAPDH control gene using ∆Cq to retain saline control groups. Data shown
represent normalized values obtained using 2-(∆Cq). The impact of sex and treatment on
activated microglia and cytokine mRNA levels were analyzed by two-way ANOVAs, with
Tukey’s post-hoc analysis, using SigmaPlot. Bivariate correlations were performed for
estrus cycle and cytokine expression using Spearman’s test. PCR data are presented
as 2-(∆Cq) normalized means ±SEM; p≤0.05 was considered significant.
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Table 2. Chapter 3 primer sequences for qPCR of inflammatory cytokines
Forward
GAG GTG ACC GCA TCT TCT TG
GAPDH
Reverse
CCG ACC TTC ACC ATC TTG TC
Forward

CCC TGA AGG ATG TGA TCA TTG

Reverse

GGC AAA GGG TTT CTC CAC TT

Forward

AAG ACC CAA GCA CCT TCT TT

Reverse

AGA CAG CAC GAG GCA TTT TT

Forward

TGT ACC TTA TCT ACT CCC AGG TTC TCT

Reverse

GTG TGG GTG AGG AGC ACG TA

Forward

TGT ACC TTA TCT ACT CCC AGG TTC TCT

Reverse

GTG TGG GTG AGG AGC ACG TA

IL-1β

IL-6

IL-10

TNF

Experiment 1: Does the administration of M6G eliminate sex differences in
analgesia?
Cannula implantation and behavioral testing. To determine if M6G produces
equipotent analgesia in males and females, thermal nociception was assessed using
the paw thermal stimulator immediately following a single injection of M6G into the
vlPAG. Following baseline PWL measures, animals received a single injection of M6G
(0.2ug or 0.7ug) into the PAG (Mathes and Kanarek, 2006) and immediately placed
back into the testing chamber. PWL was measured every 10 minutes for 120 minutes
following injection. A separate group of animals received a single injection of morphine
as a positive control (7 µg/0.25 µl/side; (Loyd et al., 2008a)), or saline as a negative
control (0.25 ul/side), resulting in 4 total groups: Saline (n=9 males, 7 females),
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Morphine (n= 8 males, 16 females), M6G Low-Dose (n=9 males, 10 females), M6G
High Dose (n=10 males).
To confirm action of M6G at μ opioid receptor and not TLR4, animals received a
single injection of M6G at the effective dose (0.2 ug in females, 0.7ug in males),
followed by a single subcutaneous injection of (-)-naloxone (3.7 mg/kg; (Wu et al.,
1997)) or (+)-naloxone (8.0 mg/kg) immediately following the PWL measurement at the
20-min time-point. This resulted in 4 additional groups: Saline + (-)-naloxone (n= 6
males, 4 females), M6G + (-)-naloxone (n= 7 males, 5 females), Saline + (+)-naloxone
(n= 5 males, 5 females), and M6G + (+)-naloxone (n= 7 males, 6 females). Animals
treated with Saline and (-)-naloxone or (+)-naloxone are not statistically different from
Saline-only animals, therefore, these groups are pooled for analysis and presentation
(data not shown).
Data analysis and presentation. Paw withdrawal latency was normalized to
%MPE and analyzed using SigmaPlot. Maximum analgesic effects of M6G and
morphine were observed between 10-60 minutes post-injection, therefore, data are
analyzed across the first 60 minutes. Data were analyzed by group across time using a
two-way repeated measures ANOVA with Greenhouse-Geisser correction when
appropriate using SigmaPlot. Area under the curve (AUC) was also calculated using
%MPE data and analyzed using two-way ANOVAs. Tukey’s post hoc tests were used
for all ANOVAs; values of p≤0.05 were considered statistically significant.
Examination and presentation of immunomodulatory cytokines using qPCR. To
determine if M6G activates microglia via TLR4, brain tissue was collected from animals
in Experiment 1.1 for analysis of inflammatory cytokines using qPCR.
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Experiment 2: Does M3G alter morphine analgesia via TLR4?
Intra-vlPAG cannulae implantation and injections. To determine if PAG TLR4
activation with M3G impacts morphine analgesia, animals were implanted with bilateral
cannula aimed at the vlPAG. On the day of testing, animals received a single intra-PAG
injection of M3G (0.075 μg/0.25 μl/side; NIDA) or saline (0.25 μl/side). Comparable
doses have been shown to increase glial activation and cytokine expression when
administered intrathecally (Lewis et al., 2010).
Approximately 45 minutes following the initial injection of M3G, behavior testing
was used to calculate morphine ED50 values using our cumulative dosing paradigm.
Briefly, animals received an injection of morphine every 20 minutes, resulting in
cumulative doses of 1.8, 3.2, 5.6, 8.0, 10.0, and 18 mg/kg. Control animals received
repeated saline injections (1ml/kg; s.c). A total of four primary treatment groups were
generated: Saline+Saline (n=5 males, 5 females), M3G+Saline (n=8 males, 7 females),
Saline+Morphine (n=5 males, 7 females), and M3G+Morphine (n=9 males, 7 females).
To determine if M3G activation occurs via TLR4, a separate group of animals
receiving intra-PAG M3G also received a peripheral injection of the TLR4 antagonist
(+)-naloxone (s.c.; 8mg/kg) immediately prior to behavioral testing. This dose was
chosen based on previous studies demonstrating inhibition of morphine-induced TLR4
activation of microglia within the PAG (Eidson and Murphy, 2013a). Two additional
groups were generated to test the effects of M3G at TLR4: Saline + (+)-naloxone (n=4
males, 4 females), and M3G + (+)-naloxone (n=8 males, 8 females). Animals treated
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with Saline + (+)-naloxone were not statistically different from animals treated with
Saline-only, therefore these groups are pooled (data not shown).
Data analysis and presentation. For morphine-treated animals, half-maximal
antinociceptive effect (ED50) and 95% confidence intervals (CI) were calculated from
dose–response curves using Graph-Pad PRISM software. To generate curves, data
was normalized such that each individual animal’s baseline PWL score = 0% and 20s =
100% (Morgan et al., 2006; Eidson and Murphy, 2013a; Eidson et al., 2016). Repeated
measures ANOVA was used to assess for significant treatment effects, with
Bonferroni’s post hoc tests where appropriate. GraphPad PRISM does not generate
exact p-values, therefore these values are presented as p< or >0.05; values of p≤0.05
were considered statistically significant.
Examination and presentation of immunomodulatory cytokines using qPCR. To
determine of M3G sex-specifically alters glial activation via TLR4, brain tissue was
collected from animals in Experiment 2.1 for analysis of inflammatory cytokines using
qPCR.
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Results
Experiment 1a: M6G is more effective in females
Exogenous M6G produces robust analgesia, and is reported to have greater
potency than morphine presumably by acting exclusively via MOR, therefore bypassing
the opposing effects mediated by TLR4 (Abbott and Palmour, 1988; Christrup, 1997;
Kilpatrick and Smith, 2005)]. To test the hypothesis that M6G activation of MOR (and
not TLR4), results in equipotent analgesia, animals received a single injection of M6G
(0.2ug), morphine (7.0ug) or saline directly into the vlPAG.
Across the initial 60 minutes following intra-PAG injections, a significant
interaction was observed between group and time (F(36,306)= 5.80, p<0.001); Figure
3.3.1a. As expected, morphine significantly increased analgesia in both males (p=0.002)
and females (p<0.001) compared with saline controls. Morphine produced greater
analgesia in males than in females 30-60 minutes post-injection, with males having
significantly greater analgesia at 40-minutes post-injection (p=0.04; Figure 3.3.1b).
Administration of M6G to females resulted in robust analgesia. Indeed, this
response was greater than females receiving morphine alone, however, these groups
were not statistically different (Average MPE: 69% vs 87%; p=0.07). Interestingly, M6G
at low doses was significantly more effective in females than in males (p= 0.007).
Although males receiving low-dose M6G had greater analgesia than saline-treated
males, these groups were not statistically different (Average MPE: 59% vs 34%;
p=0.08). To determine if the discrepancy in M6G analgesia between males and females
was due to differences in drug potency, a higher dose of M6G (0.7ug) was also
administered. Males were maximally analgesic at high doses of M6G, and did not
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significantly differ from females receiving low-dose M6G (p=0.99) or from males
receiving morphine (p=0.46). High-dose M6G was fatal in females, and this dose was
discontinued following pilot studies.

Mechanisms of M6G analgesia
Administration of (-)-naloxone significantly and completely antagonized the
analgesic effects of M6G in both males (p<0.001) and females (p<0.001); F(15,147)=2.12,
p=0.02, Figure 3.3.2a. Indeed, within 20 minutes of administration, PWLs were not
significantly different from saline in males (p=0.54) or females (p=0.49). By contrast,
administration of the TLR4 antagonist (+)-naloxone had no effect on M6G-induced
analgesia in either males (p=0.90) or females (p=0.99); F(15,153)=2.17, p=0.018; Figure
3.3.2b. Administration of either (-)-naloxone or (+)-naloxone had no effect on PWL
latency alone in males (p>0.99 and p>0.99) or females (p>0.99 and p>0.99,
respectively). Together, these results suggest that the analgesic effects of M6G are
mediated via an action at MOR, and not TLR4.
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Figure 3.3.1. M6G Induces Robust Analgesia in Both Sexes, but is More Potent in Females.
a) M6G induces robust analgesia in both sexes. Low dose M6G (0.2ug) was effective in females but not
males. b) At 40 minutes post-injection, at the time of peak morphine analgesia, significant sex differences
were observed between morphine treated males and females. Effective doses of M6G (0.2ug in females,
0.7ug in males) did not show significant sex differences at 40 minutes, or c) across the first 60 minutes of
the test. Saline (n=9 males, 7 females), Morphine (n= 8 males, 16 females), M6G Low-Dose (n=9 males,
10 females), M6G High Dose (n=10 males).
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Figure 3.3.2. Receptor Mechanisms Underlying M6G Analgesia.
a) Inhibition of MOR with (-)-naloxone (s.c.) results in complete blockade of M6G analgesia, while b)
inhibition of TLR4 with (+)-naloxone (s.c.) has no effect on PWL. Saline + (-)-naloxone (n= 6 males, 4
females), M6G + (-)-naloxone (n= 7 males, 5 females), Saline + (+)-naloxone (n= 5 males, 5 females),
and M6G + (+)-naloxone (n= 7 males, 6 females).
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Experiment 1b – M6G does not alter cytokine profiles
M6G has immunomodulatory effects on peripheral immune function, resulting in
reduced cytokine production, decreased B cell and lymphocyte proliferation, and
reduced natural killer cell activity (Thomas et al., 1995; Carrigan and Lysle, 2001).
However, it is unknown if M6G is capable of altering central cytokine concentrations.
Therefore, qPCR was used to determine cytokine expression in the vlPAG of morphineand M6G-treated males and females from experiment 1a; Figure 3.3.3.
Significant treatment effects were found for IL-6 (F(4,70) =5.86, p<0.001) and IL-10
(F(4,72) =2.97, p=0.026), while significant interactions were found for IL-1β (F(4,66) =6.58,
p<0.001), and TNF (F(4,70) =3.28, p=0.017). No significant main effects of sex were
observed. In females, IL-1β expression was significantly increased with M6G relative to
Saline (p<0.001), Morphine (p=0.002), and M6G + (+)-naloxone (p=0.002), Figure
3.3.3a. Morphine significantly increased IL-1β expression in males relative to saline
(p=0.002). Morphine also increased expression of IL-6 and TNF in females relative to
saline (p=0.004 and p=0.005, respectively). Intra-PAG M6G did not have a significant
impact on cytokine expression of IL-6, TNF, or IL-10 within the PAG for either males or
females.
Treatment with peripheral (-)-naloxone or (+)-naloxone following M6G
administration had inconsistent effects on cytokine expression. Females receiving
M6G+ (-)-naloxone showed significantly increased TNF relative to their male
counterparts (p=0.009), as well as females treated with M6G alone (p=0.02), Figure
3.3.3c. Females receiving M6G + (+)-naloxone also showed significantly increased TNF
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relative to their male counterparts (p=0.003), as well as increased IL-10 expression
relative to females treated with M6G alone (p=0.04), Figure 3.3.3d.

Figure 3.3.3. M6G Immunomodulation in the PAG.
a) IL-1β was significantly increased in M6G treated females relative to Saline and Morphine-treated
females, M6G + (+)-naloxone females, and M6G males. b) IL-6 expression was significantly increased in
morphine-treated females relative to saline females. C) TNF expression is significantly greater in
Morphine females relative to Saline controls. TNF was also expressed significantly more in M6G + (-)naloxone females relative to females treated with M6G only, as well as M6G + (-)-naloxone males. Sex
differences were observed in the M6G + (+)-naloxone group. d) IL-10 expression was significantly
increased in M6G + (+)-naloxone females relative to females treated with M6G alone. Saline (n=14
males, 12-13 females), Morphine (n= 4-6 males, 5-7 females), M6G Low-Dose (n=5 females), M6G High
Dose (n=4-5 males), M6G+(-)-naloxone (n=5-6 males, 5-6 females), and M6G+(+)-naloxone (n=5 males,
6-7 females).
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Experiment 2a: M3G attenuates morphine analgesia in males only
Previous studies reported that the morphine metabolite M3G, binds to TLR4,
producing allodynia and hyperalgesia, actively opposing the analgesic effects of
morphine and M6G (Yaksh et al., 1986; Smith et al., 1990; Ekblom et al., 1993; Bartlett
et al., 1994; Smith and Smith, 1995; Angst and Clark, 2006). To determine if M3G
induced hyperalgesia or morphine opposition in a sex-specific manner, a single injection
of M3G (0.075 ug) or saline was administered into the vlPAG of male and female rats
45 min. prior to receiving cumulative injections of morphine or saline.
Repeated measures ANOVA of morphine-treated groups shows significant effect
of treatment across time; F(3,27)= 6.54, p=0.004; Figure 3.3.4. Consistent with our
previous studies, morphine ED50 was significantly greater in females than males (ED50=
7.81 and 5.00 respectively), indicating greater morphine efficacy in males (p<0.05).
Interestingly, pre-treatment with M3G significantly attenuated morphine analgesia in
males only (p<0.01), completely abolishing the sex difference in morphine response
(ED50= 10.28 and 8.82 in males and females, respectively p>0.05); Figure 3.3.4a.
We observed a significant effect of treatment, regardless of time in saline-treated
groups; F(7,245)=9.00, p<0.001; Figure 3.3.4b. No sex differences in baseline responses
to the thermal stimulus were noted in our saline control groups (p=0.64). In addition,
M3G alone did not significantly alter response latencies from saline control within male
(p=0.99) or female (p=0.94) groups. M3G marginally increased PWL in males (AUC
61.7s vs 68.2s) and decreased it in females (AUC 57.9s vs 55.5s), such that a
significant sex difference was observed in M3G-treated animals (p=0.003).
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To determine if M3G was acting in a TLR4-dependent manner, the TLR4-specific
antagonist (+)-naloxone was administered immediately following M3G. Male and female
groups receiving only (+)-naloxone were significantly different from one another
(p=0.04). Interestingly, (+)-naloxone had no effect on M3G-treated males (p=1.0) or
females (p=0.67) compared with M3G alone, and no sex differences were observed
between males and females treated with M3G + (+)-naloxone (p=0.17); Figure 3.3.4b.
Together, these data demonstrate that increased concentrations of M3G in the
PAG are sufficient to attenuate morphine antinociception in males. However, no
statistically significant effects of M3G alone or in combination with (+)-naloxone were
observed.
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Figure 3.3.4. M3G Attenuates Morphine Analgesia in Male, but not Female, Rats.
a) Intra-PAG administration of M3G significantly attenuates morphine analgesia in males, but not females;
Saline+Morphine (n=5 males, 7 females), and M3G+Morphine (n=9 males, 7 females). b) M3G alone was
not sufficient to induce observable changes in PWL, and was not changed with (+)-naloxone;
Saline+Saline (n=5 males, 5 females), M3G+Saline (n=8 males, 7 females), Saline+Naloxone (n=4
males, 4 females), and M3G+Naloxone (n=8 males, 8 females).
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Experiment 2b: M3G alters cytokine profiles
M3G is known to induce pro-inflammatory responses that oppose the analgesic
effects of morphine (Lewis et al., 2010; Due et al., 2012; Grace et al., 2014; Xie et al.,
2017). To determine if M3G induced comparable levels of neuroinflammation in males
and females in vivo, PAG punches were collected in experiment 2a following behavior
testing, and cytokines were measured using qPCR.
A significant interaction effect was observed for IL-1β (F(4,61) =3.01, p=0.026).
Females treated with M3G+Morphine had significantly higher levels of IL-1β expression
than females receiving morphine alone (p=0.009), or males receiving M3G+Morphine
(p=0.04); Figure 3.3.5a. A main effect of treatment was observed for IL-6 (F(4,63) =5.23,
p<0.001). Regardless of sex, M3G+Morphine treated animals had greater IL-6
expression relative to groups treated with morphine alone (p=0.019); Figure 3.3.5b.
Main effects of both sex and treatment were observed for TNF (F(4,65) =10.24, p=0.002
and F(1,65) =4.99, p=0.002, respectively), however no interaction effects were observed.
Females treated with M3G alone had significantly more TNF expression than females
treated with morphine (p=0.005), or M3G-treated males (p=0.02); Figure 3.3.5c. No
significant main effects or interactions were detected for IL-10; Figure 3.3.5d. Indeed,
IL-10 levels were remarkably stable regardless of treatment or sex. Surprisingly, (+)naloxone administration did not block M3G-induced increases in IL-1β, IL-6, or TNF.
Overall, neither subcutaneous morphine nor intra-PAG M3G administration were
sufficient to alter cytokine expression in the vlPAG relative to Saline groups. However,
the combination of M3G+Morphine significantly increased IL-1β in females and IL-6 in
both sexes. Although M3G has been previously shown to augment cytokine levels in a
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TLR4-dependent manner in vitro, co-administration of the TLR4 antagonist (+)-naloxone
did not significantly impact M3G-induced increases in IL-1β, IL-6, and TNF.

Figure 3.3.5. M3G Immunomodulation in the PAG.
a) IL-1β and b) IL-6 expression significantly increased in M3G+Morphine treated females relative to
morphine-only controls. Sex differences in IL-1β expression were observed between males and females
treated with M3G + (+)-naloxone. c) TNF expression significantly increased in M3G females relative to
morphine females as well as M3G males. Significant sex differences were observed in TNF expression
between males and females treated with M3G + (+)-naloxone. d) No changes in IL-10 expression were
observed between any treatment groups. Saline (n=9 males, 8 females), M3G+Saline (n=5-7 males, 5-6
females), Saline+Morphine (n=5 males, 6-7 females), M3G+Morphine (n=6-7 males, 6-7 females), and
M3G+Naloxone (n=5-6 males, 5-6 females).
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Discussion
The present study examined both the behavioral and immunomodulatory effects
of the morphine metabolites, M3G and M6G. Intra-PAG administration of M6G results in
significantly greater analgesia in females than in males. Importantly, M6G resulted in
near maximal analgesia in females, a 26% increase from maximal morphine analgesia.
In both males and females, M6G analgesia was reversed with (-)-naloxone but
was unchanged with (+)-naloxone, consistent with previous studies showing that M6G
acts at MOR, but not glial TLR4 (Abbott and Palmour, 1988; Wittwer and Kern, 2006;
Hutchinson et al., 2010). M3G administration resulted in a significant rightward shift in
the morphine dose response curve, in males only. In contrast, pretreatment with M3G in
females did not alter the response to morphine, suggesting a ceiling effect of M3G.
Despite the large and significant shifts in pain sensitivity observed following M6G
administration in males and females, M6G did not reliably alter vlPAG proinflammatory
cytokine concentrations, and were also not consistently changed with either (-)naloxone or (+)-naloxone. In contrast, concentrations of pro-inflammatory molecules in
females treated with M3G alone or in combination with morphine were significantly
increased, although these effects were not reversible with (+)-naloxone in either sex.
Together, these data indicate that M3G may contribute to the attenuation of morphine
analgesia observed in females, as administration of M6G, but not M3G and/or morphine
results in significantly greater analgesia relative to males. These studies suggest that
the immunomodulatory effects of morphine and its metabolites result in sex-dependent
effects on pain modulation, and have far-reaching implications for the use of opioids to
treat pain in women.
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Sex differences in pharmacokinetics
Previous dogma held that there were no sex differences in morphine metabolism,
likely due to a history of conflicting HPLC results in human studies showing both the
presence (Murthy et al., 2002) and absence (Sarton et al., 2000; Romberg et al., 2004)
of sex differences in M3G or M6G concentrations following morphine treatment.
However, pre-clinical studies in rats have consistently reported significant sex
differences in metabolite concentrations using HPLC (South et al., 2001; Baker and
Ratka, 2002; South et al., 2009), with a single exception, see (Cicero et al., 1997). To
date, few studies have examined the effect of endogenous morphine metabolites on
pain modulation—and to our knowledge, the present experiments are the first to
demonstrate sex-specific causal relationships.
Results from pharmacokinetic studies also support sex-specific differences in
morphine metabolism. In humans, morphine is metabolized by isozymes in the uridine
5'-diphospho-glucuronosyltransferase (UGT) 1 and 2 subfamilies, almost all
preferentially synthesizing M3G over M6G (~45-55% and 15% of metabolized product,
respectively; (De Gregori et al., 2012)). Importantly, sex differences in the expression of
UGT1 and 2 subclasses of enzymes have been reported in humans (Gallagher et al.,
2010) and rats (Iwano et al., 2012). Further, the enzymes metabolize, and are directly
influenced by, steroid hormones (Strasser et al., 1997). In rats, gonadectomy
significantly decreases the M3G:morphine ratio in females only, suggesting the
involvement of steroid hormones in mediating sex differences in morphine metabolism
(Baker and Ratka, 2002). To date, no studies have examined the effects of sex or
gonadal hormones on the expression of these isozymes in brain tissue.
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Immunomodulatory effects of morphine metabolites
M6G is a known immunomodulator, with predominantly anti-inflammatory effects
(Thomas et al., 1995; Carrigan and Lysle, 2001), although the exact mechanism
through which M6G exerts its effects on immune function is uncertain. Here, M6G
increased expression of IL-1β, but did not change expression of IL-6, TNF, and IL-10
relative to saline controls. Antinociceptive and immunomodulatory effects of M6G have
been classically attributed to neuronal MOR (Carrigan and Lysle, 2001; Lysle and
Carrigan, 2001); however, no studies have investigated the possibility of M6G exerting
its effects via MOR on CNS glial cells, which may account for the discrepancies in
immune modulation between previous and present studies (Gessi et al., 2016).
Inflammatory mechanisms of M3G have been established, as M3G significantly
increases pro-inflammatory IL-1β mRNA in BV-2 microglia cultures (Lewis et al., 2010).
TLR4 activation by M3G is modest relative to TLR4’s natural agonist lipopolysaccharide
(LPS; (Hutchinson et al., 2010)), and may not induce robust increases cytokine
concentrations in vivo (Lewis et al., 2010; Xie et al., 2017). In the present study, we
report that M3G, administered in combination with morphine, results in increased
expression of IL-1β in females and IL-6 in both sexes relative to saline-treated controls.
However, M3G alone was not sufficient to alter cytokine expression in the PAG,
suggesting that, in vivo, central M3G does not produce measurable immune activation
relative to peripheral LPS, which has robust sex-specific effects on cytokine expression
in the PAG (Doyle et al., 2017).
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Overall, patterns of cytokine expression observed following M3G or M6G
treatment were equivocal, and not consistently reversed with (+)-naloxone or (-)naloxone. Similar inconsistencies have been reported, suggesting a complicated role for
morphine metabolites and their relative contributions to immune modulation following
morphine (Thomas et al., 1995; Hashiguchi et al., 2005). Estrus cycle was monitored in
the present experiments, however, stage of estrus did not correlate with the observed
variability in qPCR results. A number of other factors may play a role; for example, route
of drug administration [intracerebroventricular vs. subcutaneous (Hashiguchi et al.,
1998)], and duration [acute vs. chronic administration; (Eckhardt et al., 2000)] have
been shown to alter metabolite-induced, immune-related activity. Immune modulation by
M3G and M6G remains vastly understudied, and further experiments comparing brain
cytokine concentrations using various doses, time-points, and routes of administration
will be useful to understand how M3G and M6G each contribute to immune modulation.
Behavioral effects of morphine-6-glucuronide
In the present study, we hypothesized that in the absence of immune activation
by M3G or morphine, M6G would produce equipotent analgesia in males and females.
This is supported by a study in healthy human subjects demonstrating no sex
differences in analgesic responses to M6G between males and females (Romberg et
al., 2004). Surprisingly, we found that exogenous administration of M6G produces
significantly greater analgesia in females than in males. Along with our previous data,
this finding provides a new converging line of evidence to support our hypothesis that
TLR4 is a primary contributor to sex differences in morphine action. It also initiates
exciting and important questions regarding the mechanisms of opioid analgesia;
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specifically, why and how does M6G produce robust analgesia in females compared
with many other opioids that produce more potent analgesia in males (Barrett et al.,
2002; Terner et al., 2003; Stoffel et al., 2005; Peckham and Traynor, 2006; Bai et al.,
2015)?
One possible explanation for the reversal of sex differences observed with M6G,
is that M6G is able to better utilize MOR than morphine. The PAG sends dense
projections to the rostral ventromedial medulla (RVM), which together with descending
projections to the spinal cord dorsal horn, constitute the endogenous descending
analgesia circuit. Previous analtomical studies in our lab have reported that the density
of PAG-RVM output neurons is significantly greter in females frompared with males.
However, despite this difference in the number of projection neruons, the percent of
PAG-RVM neurons activated by morphine is significantly greater in males (20% vs
50%) (Loyd and Murphy, 2006; Loyd et al., 2008b). Based on the resuls of the present
study, we would predict that M6G activates a greater proportion of PAG-RVM neurons
than morphine in females than in males, resulting in improved analgesia. Further
investigation of the binding properties of M6G in males and females is clearly
warranted.
Behavioral effects of morphine-3-glucuronide
Interestingly, the present study shows that injection of M3G into the vlPAG prior
to morphine administration causes a significant attenuation of morphine analgesia in
males only. It has been previously reported that female rats metabolize approximately
2-3 times more M3G than their male counterparts following a single systemic injection of
morphine (Baker and Ratka, 2002; South et al., 2009). M3G levels are significantly
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higher in females following morphine; therefore, we suspect that the lack of behavioral
effect observed in females is due to saturation of M3G at TLR4 (i.e., a ceiling effect of
M3G). This interpretation is consistent with our hypothesis that increased M3G reduces
morphine’s effects, and may contribute to sexually dimorphic responses to morphine.
We did not observe changes in PWL with administration of M3G alone. This is
likely due to discrepancies in testing procedures, as previous studies examining M3G
adjusted baseline PWL to ~10s in order to observe hyperalgesia (Lewis et al., 2010).
However, the present experiments used a lower baseline threshold (approx. 4-7s;
consistent with our previous studies (Loyd et al., 2008a; Eidson and Murphy, 2013a)) to
accommodate increases in PWL as a result of morphine administration. This may have
created a behavioral floor effect for animals treated with M3G alone, and decreases in
PWL due to hyperalgesia may not be statistically observable at the current threshold.
The sex-specific effects we observe here with M3G have broad implications that
apply to other opioids that create 3-glucuronide metabolites. Glucuronidation at the 3site of the substrate molecule is associated with glial activation and neuronal excitability;
for example, morphine-3-glucuronide (Lewis et al., 2010) and estradiol-3-glucuronide
(Lewis et al., 2015), activate glial cells in a TLR4-dependent manner, increasing the
release of pro-inflammatory mediators, ultimately resulting in increased neuronal
excitation. Hydromorphone-3-glucuronide (Smith, 2000) and normorphine-3-glucuronide
(Smith et al., 1997) also have been shown to increase neuronal excitability, likely
through the same mechanisms. Interestingly, exogenous opioids with the greatest sex
difference in ED50 in rats (oxymorphone, hydromorphone, and morphine (Peckham and
Traynor, 2006)) all produce 3-glucuronide metabolites by Phase II metabolism via
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UGTs. In contrast, drugs producing comparable ED50’s in males and females (codeine,
oxycodone, fentanyl) undergo Phase I metabolism by cytochrome P450 (CYP)
enzymes, and therefore do not produce 3-glucuronide metabolites on their first pass
(Holtman and Wala, 2006; Chan et al., 2008; Smith, 2009). More research is needed to
understand how metabolism and elimination of these drugs may differ in males and
females, and how 3-glucuronide metabolites impact analgesia.
Together, these data demonstrate an important proof of principle: that in the
absence of TLR4 signaling, opioid analgesia is equally effective—if not more effective—
in females than in males. Historically, M6G has not been used for the treatment of
clinical pain in humans. This is perhaps due to its “low and slow” blood brain barrier
permeability, high variability in the doses of M6G required to induce analgesia
(depending on the type of pain and method of administration), and tendency to
accumulate in plasma in patients with impaired renal function [see (Lotsch and
Geisslinger, 2001; Kilpatrick and Smith, 2005) for review]. However, clinical trials of
M6G demonstrate comparable analgesia to morphine at appropriate doses, while
reducing the negative side effects typically associated with morphine, such as nausea
and sedation, in both men and women (Cann et al., 2002; Romberg et al., 2004; Hanna
et al., 2005; Dahan et al., 2008). Clearly, further research is required to address the
relevance of treatment with M6G, as these studies may provide insight into improved
treatment strategies for pain management in females.
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4

GENERAL DISCUSSION

Summary: Sex differences in vlPAG glial activity significantly contribute to
morphine efficacy via TLR4
Opioids are the most commonly used prescription medications for severe pain, with
approximately 1 in 5 Americans prescribed opioids each year (Daubresse et al., 2013).
Women are more likely than men to suffer from chronic inflammatory conditions, and to
be prescribed opioid drugs for the treatment of pain (Frenk et al., 2015). Unfortunately,
women experience increased negative side effects of opiate use (Fillingim et al., 2009),
and decreased analgesic efficacy relative to men (Cepeda and Carr, 2003). Rodent
studies from our lab and others demonstrate that females require approximately two
times as much morphine to achieve analgesia comparable to males (Craft et al., 1999;
Ji et al., 2006; Wang et al., 2006; Loyd et al., 2008b).
Many mechanisms have been identified as contributing to the dimorphic effects of
morphine, including reproductive hormones (Craft, 2007), GABA, glutamate and
melanocortin-1 signaling (Mao, 1999; Tonsfeldt et al., 2016), and MOR density and tone
(Loyd and Murphy, 2014) [see Table 3]. The fact that so many seemingly competitive
theories exist to account for the dimorphic response to morphine implies a parallel
and/or upstream mediator of these effects. Given the inverse relationship between glial
activation and analgesia [see Table 4], and the known contribution of glial TLR4 to
modulate morphine analgesia in male rats (Eidson and Murphy, 2013a) we
hypothesized that sex differences in innate immune function are a likely precursor
and/or a significant contributor to the sexually dimorphic actions of morphine.
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The data presented in Chapters 2 and 3 demonstrate that innate immune glial cells,
via TLR4 signaling, contribute to the sexually dimorphic effects of morphine in the rat.
Specifically, sex differences in microglial activation were found in the PAG, as females
have a significantly larger proportion of microglia in the PAG with an “activated”
morphology, both at baseline and following immune challenge with LPS. Although acute
morphine treatment is not sufficient to alter the morphological state of microglia in the
PAG, the percentage of endogenously activated glia in this region significantly
correlates with morphine ED50. This indicates that the baseline level of microglia
activation in the PAG can predict the dose of morphine required to elicit analgesia;
specifically, as the proportion of activated glia in the PAG increases, morphine
analgesia decreases. Importantly, we demonstrate that PAG TLR4 is both sufficient and
necessary to drive sex differences in morphine response. Activation of PAG glia with
LPS prior to morphine administration reduces male analgesia to “female-typical” levels,
and reduces or abolishes analgesia in a subset of females. On the other hand, inhibition
of PAG TLR4 with (+)-naloxone increases morphine analgesia in females, abolishing
observed sex differences in morphine response.
Further, we demonstrate that morphine metabolites have sex specific effects on
analgesia that may contribute to the sexually dimorphic response to morphine, as
increased concentrations of M3G in the PAG prior to morphine administration decrease
male analgesia to “female-typical” levels, similar to LPS, abolishing sex differences in
analgesia. With administration of M6G, female analgesia not only matches, but
surpasses male analgesia—suggesting that in the absence of TLR4-induced signaling,
sex differences in response to opioids are reversed.
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Current hypotheses underlying sex differences in morphine analgesia are
linked with glial activity
Together, the present body of work strongly implicates PAG TLR4 in driving the
sex differences in morphine analgesia, and suggests that opioid efficacy is dependent
upon glial activation in the PAG. Indeed, previous hypotheses that have been proposed
to underlie sex differences in morphine analgesia are all directly linked with glial activity:

Estradiol
Studies employing a variety of techniques and pain modalities have assessed the
role of steroid hormones, and in particular estradiol, in modulating pain and opiate
analgesia. In terms of basal sensitivity, the majority of preclinical studies report no
differences in somatosensory thresholds across the estrus cycle, although pro- and antinociceptive effects of estradiol have also been reported (Craft, 2007; Craft et al., 2008).
In terms of opiate analgesia, several general claims can be made regarding the role of
hormones in preclinical studies using rodents [for review, see (Craft et al., 2004)]: (1)
morphine is most efficacious in intact males and gonadectomized males supplemented
with testosterone; (2) morphine is least efficacious in females supplemented with
estradiol; and (3) in normally cycling females, morphine responses are decreased in
proestrus and estrus stages, when circulating hormones peak, relative to diestrus.
Together, this body of literature suggests that female hormones, specifically estradiol,
decreases the analgesic potency of morphine.
Estradiol is a contributing factor in sex differences in immune function. CNS
immune cells, specifically astrocytes, express the enzymes 5a-reductase and 3a-
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hydroxysteroid dehydrogenase) and are implicated in both progesterone and
testosterone metabolism (Garcia-Segura and Melcangi, 2006). Glial cells do not
express aromatase for the conversion of testosterone into estradiol under normal
conditions (Garcia-Segura and Melcangi, 2006); however, astrocytes and microglia
possess steroid hormone receptors, including estrogen receptor alpha (ERα), making
them susceptible to changes in estradiol across the estrus/menstrual cycle (Sierra et al.,
2008).
Estradiol has a well-documented biphasic effect on immune function in both
preclinical and clinical studies (Whitacre et al., 1999; Nilsson, 2007; Straub, 2007), and
its pro- or anti-inflammatory effects are dependent upon dose, time, and method of
testing (in vitro vs. in vivo). For example, high levels of estradiol (typical of pregnancy)
decrease proinflammatory cytokine production and attenuate inflammatory responses to
LPS (Vegeto et al., 2003; Dimayuga et al., 2005; Lewis et al., 2008). In contrast, low
doses of estradiol, comparable to normal circulating levels, increase peripheral
concentrations of proinflammatory cytokines (Correale et al., 1998). Removal of
endogenous estrogens decreases cytokine production and cell-surface expression of
TLR4 (Rettew et al., 2009). Estradiol also influences cytokine release in a timedependent fashion, as chronic but not acute estradiol administration increases TLR4mediated pro-inflammatory responses in immune cells of females compared with males
(Soucy et al., 2005; Calippe et al., 2008; Calippe et al., 2010), and potentiates LPSevoked TLR4 immune responses in vitro (Loram et al., 2012). Estradiol effects may also
be dependent upon the setting, as in vitro administration is often anti-inflammatory
(Drew and Chavis, 2000), but estradiol administered in vivo results in pro-inflammatory
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responses (Soucy et al., 2005; Calippe et al., 2008; Rettew et al., 2009; Loram et al.,
2012). Overall, these data suggest that 1) glial cells are responsive to gonadal
hormones, and 2) low-dose, chronic estradiol may create a more pro-inflammatory
environment in vivo.
These conclusions are consistent with the present studies, as increased glial
activation was observed in intact females in the PAG at baseline, suggesting that glial
cells are innately more activated in females than in males. In addition, LPS immune
challenge had a greater effect on females, increasing pro-inflammatory IL-1β, ‘activated’
microglial morphological subtypes, and completely abolishing morphine analgesia in a
subset of females. To examine the system in its most physiologically relevant state,
estrus cycle was monitored but not controlled throughout our experiments. Estrus cycle
did not correlate with measures of glial activation in the present data, reinforcing the
notion that the interaction between estradiol and immune function is context dependent.
Future studies examining gonadectomized vs. intact animals may elucidate the role of
estradiol on TLR4 in the observed effects on morphine analgesia.

GABA and glutamate signaling
The antinociceptive effects of opiates are mediated, in part, through removal of
GABAA-mediated inhibition on excitatory glutamatergic vlPAG neurons that project to
the RVM and spinal cord [for review, see (Lau and Vaughan, 2014)]. Blocking GABAA
receptor signaling, or administration of μ opioid receptor agonists, hyperpolarizes
GABAergic interneurons to decrease (or disinhibit) GABA signaling and facilitate opioid
analgesia (Vaughan et al., 1997). Dimorphic GABAergic and glutamatergic signaling
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within the PAG and RVM have been identified as contributing factors to sex differences
in opiate analgesia. GABA has been shown to influence the antinociceptive effects of
morphine in a sex-dependent manner. Consistent with the dimorphic effects observed
following intra-PAG morphine (Krzanowska and Bodnar, 1999; Loyd et al., 2008b), intraPAG administration of the GABA antagonist bicuculline produces greater analgesia in
male rats (Bobeck et al., 2009). Further, chronic peripheral inflammatory pain decreases
tonic GABAA-mediated currents and increases the efficacy of systemic morphine in
females, an effect reversed by potentiation of GABAA receptor currents (Tonsfeldt et al.,
2016).
Glutamatergic NMDA receptors have also been implicated in the sexually
dimorphic response to opioids. In rats, NMDA antagonism increases morphine
analgesia in both males and females; however, this effect is highly variable and is
dependent upon the drug, dose, and nociceptive test being used (Craft and Lee, 2005;
Holtman and Wala, 2006). In male mice, blockade of NMDA receptor signaling via
systemic antagonist administration results in a complete attenuation in both the
analgesic and hyperalgesic responses to high (but not low) doses of morphine [for
review see (Mao, 1999)]. In contrast, NMDA receptor blockade results in a partial
reduction, or has no effect on, morphine analgesia in female mice (Lipa and Kavaliers,
1990; Nemmani et al., 2004; Waxman et al., 2010). These data suggest that NMDA
receptor signaling is necessary to facilitate morphine antinociception in male, but not
female mice. Using quantitative trait locus mapping in male and female mice, the
melanocortin-1 receptor (MC1R) gene was identified as a potential ‘female counterpart’
to NMDA. Genetic knockout of the Mc1r gene, or pharmacological antagonism of
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functional MC1R, produces increased μ-opioid receptor mediated analgesia and
decreased μ-opioid hyperalgesia in females, but is without effect in males (Mogil et al.,
2003; Juni et al., 2010; Arout et al., 2015). These findings, together, suggest that NMDA
and GABAA receptor signaling may be inherently different in males and females, and
contribute to the dimorphic effects of morphine.
Sex differences in glial activation likely contribute to the observed differences in
NMDA and GABA signaling [for review see (Ji et al., 2013)]. Morphine-induced
activation of microglia and astrocytes induces pro-inflammatory cytokine release, which
rapidly upregulates the expression of neuronal NMDA (Wei et al., 2008; Olmos and
Llado, 2014), and decreases cell surface expression of GABAA receptors in vitro
(Ogoshi et al., 2005; Stellwagen et al., 2005; Tilleux and Hermans, 2007; Yan et al.,
2014). Morphine-induced TNF release has also been shown to site specifically
downregulate glial GLAST and GLT-1 glutamate transporter expression in the vlPAG
(Eidson et al., 2016), leading to increased glutamate in the synapse, and increased
neuronal excitation (Mao et al., 2002). Conversely, inhibition of glial activation within the
RVM attenuates the enhanced neuronal NMDA signaling normally observed following
nerve-injury (Wei et al., 2008). Interestingly, several NMDA antagonists that reportedly
potentiate morphine analgesia (including MK-801 and ketamine) (Johnston and
Westbrook, 2005) also block microglia activation, both in vivo and in vitro (Ma et al.,
2002; Thomas and Kuhn, 2005; Murugan et al., 2011).
The sexually dimorphic response of glia to perturbation models (Drew and
Chavis, 2000; Aulock et al., 2006; Calippe et al., 2010; Loram et al., 2012; Engler et al.,
2016), in combination with the present studies, supports the possibility of downstream
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sex differences in glutamate and GABA signaling that ultimately contribute to sex
differences in opioid analgesia. Previous studies in our lab indicate that chronic
morphine is capable of altering glutamate transporters within the PAG, however these
studies were conducted exclusively in males (Eidson et al., 2016). Similarly, the
experiments described above demonstrating a link between glial activation and
glutamate/GABA signaling, when performed in vivo, were also conducted only in males
(Wei et al., 2008; Yan et al., 2014). Thus, a clear relation between glial activation and
glutamate/GABA signaling has never been investigated in females and additional
studies are clearly warranted.

Opioids and opioid receptors
Sex differences in opioidergic signaling have also been reported (Zubieta et al.,
2002; Peckham et al., 2005; Loyd and Murphy, 2006; Bernal et al., 2007; Loyd et al.,
2008b; Loyd et al., 2008a). Specifically, we have previously demonstrated that male rats
have significantly higher levels of MOR protein and radioligand binding in the vlPAG,
and respond more robustly to morphine, than females (Zubieta et al., 2002; Loyd and
Murphy, 2006; Loyd et al., 2008a; Loyd and Murphy, 2009). Indeed, MOR levels are
40% lower in proestrus females compared with males; this corresponds to the stage of
estrus when intra-PAG morphine is least effective in modulating pain (Loyd et al.,
2008a). Further, selective ablation of vlPAG MOR-expressing neurons significantly
attenuates the response to morphine in males but not females, indicating that the
density of PAG MOR expression is significantly correlated with the degree of opioid
analgesia in male, but not female, rats (Loyd et al., 2008a).
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Given that the opioid system is inextricably linked with immune function, it is
highly likely that microglia play a role in the development of sex differences in MOR
expression and signaling. Opioid receptors and their endogenous ligands communicate
bidirectionally with immune cells of the CNS, and all three opioid receptor subtypes (mu,
kappa, and delta) have been localized on immune cells, including T-cells, B-cells,
lymphocytes and macrophages [for review, see (Bidlack et al., 2006)]. Application of the
endogenous opioid met-enkephalin increases LPS-induced release of proinflammatory
IL-1β in primary brain cultures (Kowalski et al., 2002), while application of
proinflammatory IL-1β or TNFα increases pro-enkephalin expression in astrocytes
(Spruce et al., 1990). Similarly, the potent endogenous MOR agonists endomorphin 1
and 2 (EM1 and EM2) are expressed in immune cells and upregulated in response to
peripheral inflammation (Jessop et al., 2000; Mousa et al., 2002). EM2 has been shown
to modulate cytokine production (decreased TNFα and IL-10, increased IL-1β; (Azuma
and Ohura, 2002), although the mechanism whereby EM2 and immune function
contribute to the sexually dimorphic effects observed following endomorphin
administration is not clear (Liu and Gintzler, 2013; Kumar et al., 2015b; Kumar et al.,
2015a).
Neuronal MOR tone is also modified by increased glial activity in males such that
the release of proinflammatory cytokines upregulates MOR expression both in vivo (Ji et
al., 1995; Ruzicka and Akil, 1997; Mousa, 2003; Puehler et al., 2004) and in vitro
(Ruzicka et al., 1996; Borner et al., 2004). In females however, glial activation does not
similarly upregulate MOR expression (Zhang et al., 2014), suggesting that analgesia
may be buffered by an increase in MOR following immune challenge in males but not
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females. Together, these data support a bidirectional link between MOR and glia,
suggesting that increased glial cells activity may influence MOR activity, contributing to
the attenuated response to morphine observed in females. Our present data indicate
increased activity of glial cells within the PAG, which may influence MOR tone and
contribute to the dimorphic expression of MOR observed in our earlier studies (Loyd et
al., 2008a).
Our novel studies examining M6G demonstrate that in the absence of TLR4
signaling, MOR-induced analgesia is more effective in females than in males. The
reversal of sex differences in analgesic response with M6G suggests unique and sexspecific binding properties not shared by other MOR agonists (e.g. longer time at the
receptor, or increased affinity in females). M6G, though more efficacious at MOR than
morphine, has decreased affinity at the MOR receptor [see (Kilpatrick and Smith, 2005)
for review], however, the binding properties of M6G have never been compared directly
between males and females. Future studies examining MOR activation and binding by
M6G are necessary, and may reveal novel pharmacokinetic mechanisms that can be
applied to the development of new therapeutic drugs that improve analgesia in females
relative to current opioid treatments.

Alternative pain treatments further suggest a role for glia
The data presented in this dissertation suggest a clear relation between
analgesic efficacy and immune activity in females. Although a formal examination of our
hypothesis has not been performed in the clinic, human studies have been inadvertently
investigating sex differences in immune-derived pain and analgesia for quite some time.
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The use of non-steroidal anti-inflammatory drugs (NSAIDs) as an alternative treatment
in women is perhaps the most clinically relevant example of this conclusion.
NSAIDs inhibit the enzyme cyclooxygenase (COX), which is responsible for
production of inflammatory prostanoids. COX exists in two isoforms: COX-1, which is
constitutively expressed in most cells, and COX-2 which is expressed more selectively
in immune macrophages and is upregulated in response to inflammation (Hawkey,
2001; Bertolini et al., 2002). Importantly, COX-2 is a pro-inflammatory product of TLR4mediated immune signaling (Cao et al., 1997; Zhang et al., 2008; Czapski et al., 2010;
Tse et al., 2014; Gaikwad and Agrawal-Rajput, 2015). NSAIDs are commonly used in a
clinical setting to reduce inflammation, and also as an opioid adjuvant (a non-opioid
drug used to improve the efficacy of opioids, and reduce the negative side effects
associated with opioid consumption) in both men and women (Elia et al., 2005).
Despite the prevalence of NSAID use, to our knowledge only two studies have
directly investigated sex differences in the analgesic response of NSAIDs alone. Both
studies were conducted by the same laboratory, and demonstrate greater analgesic
efficacy of ibuprofen in males relative to females (Walker and Carmody, 1998; Butcher
and Carmody, 2012). Studies of sex differences in analgesic efficacy of other commonly
used NSAIDs have not been performed, however, robust sex differences have been
observed in studies examining the prevalence of overall NSAID use (Dominick et al.,
2003; Fosbol et al., 2008). Indeed, disparate incidence rates of 57% female vs. 17%
male for NSAID prescriptions for cancer pain have been reported (Shinde et al., 2015).
Interestingly, post-marketing studies show that women are the greatest consumers of
COX-2 selective inhibitors [approximately 85%; (Solomon et al., 2006)], suggesting that
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there is a much greater demand from women for drugs that reduce pain and/or improve
opioid effectiveness by decreasing inflammation.
Both preclinical and clinical studies report that co-administration of COX-2
inhibitors with morphine significantly potentiates pain-relief in both sexes (DecigaCampos et al., 2003; Pinardi et al., 2005; Reuben and Ekman, 2005; Aynehchi et al.,
2014). In studies of women following gynecological surgery, treatment with the COX-2
selective inhibitor Rofecoxib significantly attenuates both surgical pain and opioid
consumption (Sinatra et al., 2006), while treatment with parecoxib was associated with
a lower incidence of post-operative headache and greater overall satisfaction compared
with placebo (Luscombe et al., 2010). These studies are consistent with the present
data demonstrating increased analgesic efficacy of opioids in females treated with
immune-inhibiting drugs.
In further support of this conclusion, preclinical studies show that several other
non-opioid analgesics used to improve opioid efficacy in men and women are also glial
inhibitors. For example, tri-cyclic antidepressants are commonly used to improve pain
treatment (McQuay et al., 1996). The tri-cyclic paroxetine inhibits microglia activation
(Liu et al., 2014), while the tri-cyclic amitriptyline not only inhibits microglia activation,
but has been shown to directly improve morphine analgesia in male rats by reversing
morphine-induced decreases in glutamate transporter expression, and suppression of
pro-inflammatory cytokines (Tai et al., 2006). Perhaps the most relevant and highly
studied opioid adjuvant, the anti-seizure medication gabapentin, is commonly used to
improve opioid analgesia, reduce the negative side effects of opioids, and reduce opioid
consumption (Bennett, 2011; Shinde et al., 2015). Gabapentin’s primary mechanism of
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action is unclear, however, gabapentin is thought to modulate neuronal GABA synthesis
and affect calcium gated ion channels on neurons (Taylor, 1997). In addition,
gabapentin also inhibits the release of pro-inflammatory mediators (Yang et al., 2012)
and promotes the release of anti-inflammatory mediators (Dambach et al., 2014) from
microglia. Consistent with the studies presented in Chapter 2, Figure 2.3.5, gabapentin
reverses sex differences in anti-nociception induced by tramadol in mice (Dai et al.,
2008). Interestingly, when co-administered with morphine, gabapentin also reduces
M3G formation by ~33% in male rats (Papathanasiou et al., 2016).
Overall, the literature suggests a pattern, that with the absence or inhibition of
glial signaling, sex differences in anti-nociception are reduced or abolished. Inhibiting
COX-2, a pro-inflammatory product of glia, improves opioid analgesia in men and
women. Despite having vastly different effects on neurons, drugs such as gabapentin
and amitriptyline are used clinically to improve analgesia in both sexes, likely through
their similar actions on glial cells. The data presented in this dissertation directly test
and support this theme, demonstrating that direct inhibition of glial TLR4 with (+)naloxone abolishes sex differences in morphine anti-nociception, resulting in equivalent
analgesia in males and females. Further, MOR agonism in the absence of glial
activation, as is the case with M6G, results in the complete reversal of sex differences in
anti-nociception. Together, these studies outline a clear strategy for pain management:
improvements in opioid analgesia can be made by inhibiting or preventing the activation
of glia, and this may be especially beneficial for pain management in women.
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Future directions of pain treatment: Focus on the individual
Pain treatment has not changed drastically over the past two hundred years, and
opioids remain the most prevalent and highly prescribed analgesic drugs. Opioids
themselves have been altered only slightly to benefit unique types of pain, changing in
their analgesic efficacy relative to morphine; for example, less painful conditions may be
treated with the weak analgesic, codeine, and more painful conditions may be treated
with the more potent analgesic, fentanyl. However, well-known issues with opioid use,
such as the high risk of tolerance and dependence in both sexes—as well as decreased
analgesic efficacy and increased negative side-effects in women—have not been
addressed with these ‘novel’ opioids. The use of glial inhibitors to treat pain is finally
beginning to address unique mechanisms to improve the analgesic efficacy of opioids in
both sexes, and more directly reduce the negative side effects of opiate use such as
hyperalgesia, tolerance, and dependence.
As we move forward, one thing is clear: it is important to consider sex differences
in all pain research, both preclinical and clinical. It is not enough to include women in
clinical studies and ignore them during data analysis. For example, although both men
and women were included in recent clinical trials of COX-2 inhibitors, only 20% of the 28
clinical studies on rofecoxib (Cascales Perez et al., 2003), and 14% of the clinical
studies of etoricoxib (Chilet-Rosell et al., 2009) stratified or analyzed their data by sex.
Currently, examination of sex differences in the efficacy of analgesics is severely (and
disappointingly) underrepresented in both preclinical and clinical studies.
The overall message of this dissertation is not that females should be given
special treatment in pain research, rather, that men and women require different
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treatment in order to achieve equal health outcomes. Furthermore, this body of work
advocates for the study pain and immune function in both men and women because it
uniquely effects the daily lives of so many individuals suffering from pain. Preclinical
studies investigating pain and pain management should carefully consider biological sex
when planning experiments, and it should go without saying that clinical studies need to
analyze all possible aspects of their data—not just sex, but age and race as well.
Careful investigation of sex-specific effects will not only provide a more complete
understanding of the biological system but will facilitate new options for individualized
treatment in both men and women.
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Table 3. Observed Mechanisms Underlying Sex Differences in Analgesia and Hyperalgesia.
Manipulation

Sex /
Species

Drug /
Analgesic
Treatment

Nociceptive
Test

Effect on
Analgesia
(relative to
control)

Procedural
Comments

Indicates
organizational but
not activational
effects of hormones

(Cicero et al.,
2002)

Reference

Reproductive hormones

M/F; SD
rat

Morphine, s.c.

Hotplate

− Adult
Males/Females
↓ Young Males +
GDX
↑ Young
Females + T

E2 (chronic)

F; SD
rat

Morphine,
Cumulative
(total 3.2
mg/kg; s.c.)

Hotplate
Warm
water tailwithdrawal

↑ at 4h;
↓ at 24h* and
48h.

*24h for tailwithdrawal test only

(Craft et al.,
2008)

GDX

M/F;
albino
rat

Morphine (5
doses 140ug; i.c.v.)

Tail-flick,
shock

−
Males/Females

Analgesia ↓ at
proestrus but not
estrus or diestrus in
intact females

(Kepler et al.,
1989)

GDX

M/F;
albino
rat

Morphine (5
doses 110ug; intraPAG)

Hotplate

− Males
↑ Females*

*Analgesia
increased at high but
not low doses

(Krzanowska
and Bodnar,
1999)

E2, P,
E2+P4
(chronic)

OVX F;
SD rat

Morphine,
(5mg/kg s.c.)

Hotplate

↓ with E2, P4, or
E2+P4

Tail-flick

DXMP:
↑ Males
↑ Females
Ketamine:
− Males
↑ Females
MK-801:
− Males
↑ Females

Adult: GDX
Early life:
Females+T
or
Males+GDX

(Ratka and
Simpkins, 1991)

NMDA
NMDA
antagonism
(Dextrometh
orphan
[DXMP],
ketamine,
MK-801)

M/F; SD
rat

Morphine
(3mg/kg; s.c.)

NMDA
antagonism
(MK-801)

M/F
deer
mice

Morphine
(1mg/kg; i.p.)

NMDA
antagonism
(Mk-801)
±GDX

M/F;
SW
mice

Forced swim

Hotplate

Hotplate

↓ Males
↓ Females
↓ Intact Males
− Intact Females
↓ GDX Males
↓ GDX Females

Antagonist
increased F
analgesia at high
doses only

(Holtman et al.,
2003)

Complete
attenuation in males,
partial attenuation in
females

(Lipa and
Kavaliers, 1990)

(Mogil et al.,
1993)
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NMDA
antagonism
(Dextrometh
orphan
[DXMP),
Dextrorphan
[DXTP],
MK-801,
LY235959,
L-701324,
Ro25-6981)

M/F;
CD1
mice

NMDA
antagonism
(MK-801);
±
Progesteron
e

M/
OVXF
; CD1
mice

Morphine (15,
25, 35 and 45
mg/kg; i.p.)

Morphine (40
mg/kg)*

Tail-flick

Tailwithdrawal

DXMP:
↑/↓ Males
−/− Females
DXTP:
↑/− Males
−/− Females
MK-801:
↑/− Males
−/− Females
LY235959:
↑/↑ Males
↑/↑Females
L-70132:
↑/↑ Males
↑/↑Females
Ro25-6981:
−/↓ Males
−/↓Females
↑ Intact Males
− Intact Males +
P
− Intact Females
↑ OVX Females
− OVX Females +
P

*Results show
effects of
antagonists on
LOW (15, 25mg/kg) /
HIGH (35, 45 mg/kg)
doses of morphine
analgesia

(Nemmani et al.,
2004)

*Measures morphine
hyperalgesia. Here,
increased analgesia
reflects decreased
hyperalgesia

(Waxman et al.,
2010)

MOR
MOR
antagonism
MOR
antagonism

M/F;
SD
rat
M/F;
SD
rat

MOR lesions
±
inflammatory
CFA

M/F;
SD
rat

MOR
antagonism

M/F;
SD
rat

Morphine (0.3,
1.0, 3.0, or
10ug); s.c.
Fentanyl,
morphine,
buprenorphine
Morphine
Cumulative (up
to 18mg/kg);
s.c.
Morphine,
(cumulative up
to 10mg/kg);s.c.

Tail
withdrawal

↓ Males
↓ Females*

*Antagonist more
potent in females

(Bernal et al.,
2007)

Hotplate

↓ Males
↓ Females*

*Antagonist more
potent in females

(Craft et al.,
2001)

Hotplate
PWL

↓ Males
− Females

Wail
withdrawal

↓ Males
↓ Females*

(Loyd et al.,
2008a)
*Antagonist more
potent in females

(Peckham et al.,
2005)
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Table 4. Mechanisms Attributed to Sex Differences in Morphine Analgesia Share an Inverse Relation with
Inflammatory Markers.
Manipulation

Model /
Tissue

Effect on ProInflammatory
Markers

Immune
challenge

Procedural
comments

Reference

Reproductive hormones
Note: Given known discrepancies between in vitro and in vivo application of steroid hormones, studies included in
this table are limited to in vivo application of hormones only.
OVX
Female
E2 for 4 weeks
(Calippe et al.,
LPS ex vivo
E2
↑
C57BL/6J
before testing
2008)
mice
Intact M/
− Male
E2 for 12 days
LPS ex vivo
E2
OVX F; SD
(Loram et al., 2012)
↑ Female
before testing
rat
OVX
− P4
Female
E2, P4 for 5 weeks
(Rettew et al.,
LPS in vivo
E2, P4, E2+P4
↑ E2
C57BL/6
before testing
2009)
↑ E2+P4
mice
Female
↓ 24h post-LPS
CD1 and
LPS in vivo
OVX
− 3d, 7d post(Soucy et al., 2005)
C57BL/6J
LPS
mice
NMDA
NMDA
antagonism
(DXMP)
NMDA
antagonism
(MK-801)
NMDA
antagonism
(MK-801)
NMDA
antagonism
(MK-801,
DXMP)

BV2
microglia
cell line
Sex not
specified;
1d old
Wistar rat

LPS in vitro

↓

(Cheng et al.,
2015)

Hypoxia in
vivo

↓

(Murugan et al.,
2011)

M/F; rat

None

− Male
↑ Female

(Nieto-Sampedro et
al., 1991)

BV2
microglia
cell line

LPS in vitro

↓

(Thomas and Kuhn,
2005)

Chronic
constriction
injury in vivo

↓

MOR
MOR antagonist
[(-)-Naloxone]

Male; SD
rat

MOR-KO

Sex not
specified;
B6
background

Restraint
stress +
allergen

−

MOR agonism
(morphine)

Male; SD
rat

L5 spinal
nerve injury

↑

*CNS inflammation
*Suggests in the
absence of MOR,
there is no
challenge-induced
increase in
inflammation
*CNS inflammation;
Increases in
immune activation
linked with
decreases in
analgesia and
increases in
morphine tolerance

(Hutchinson et al.,
2008a)

(Okuyama et al.,
2010)

(Raghavendra et
al., 2002)
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